**Vicki Lynn Ellingrod (Ringold)**

**Curriculum Vitae**

Work Address:

University of Michigan

College of Pharmacy

428 Church Street

Ann Arbor, Michigan 48109-1065

Office: 734-615-4728

Fax: 734-763-4480

e-mail: vellingr@med.umich.edu

**EDUCATION**

1995-1996 American College of Clinical Pharmacy (ACCP), Psychopharmacology Fellowship. University of Iowa, College of Pharmacy, Iowa City, Iowa

1994-1996 Clinical Research Fellowship in Psychopharmacology. University of Iowa,

 College of Pharmacy, Iowa City, Iowa

 Major Advisor: Paul J. Perry, Ph.D.

1992-1994 Doctor of Pharmacy. University of Minnesota, Minneapolis, MN,

1989-1992 Bachelor of Science, Pharmacy, University of Minnesota, Minneapolis, MN

1986-1989 Augsburg College, Minneapolis, MN

**PROFESSIONAL EXPERIENCES**

# July 2022-present Dean, College of Pharmacy, University of Michigan

# September 2020-June 2022 Senior Associate Dean, College of Pharmacy, University of Michigan

# April 2018-present Scientific Editor, *Journal of Clinical and Translational Science*

# September 2019-present Editor, Pharmacotherapy Handbook

# October 2017-2022 Lead, Education Workgroup, Precision Health Initiative, University of Michigan

# January 2017-present Editor, *Pharmacotherapy: A Pathophysiologic Approach*

September 2016-Aug 2020 Associate Dean for Research and Graduate Education, College of Pharmacy, University of Michigan

April 2016-present Associate Director for the Michigan Institute for Clinical Health Research (MICHR), University of Michigan

# September 2015-2016 Deputy Editor, *Pharmacotherapy: A Pathophysiologic Approach, Tenth Edition*

February 2015-present Director of for the Michigan Institute for Clinical Health Research (MICHR) Education and Mentoring Group, University of Michigan

June 2014- present Faculty Lead for the Michigan Institute for Clinical Health Research (MICHR) Mentored Clinical Scientist Career Development Award Program (MICHR K), University of Michigan

November 2013- June 2015 Associate Chair, University of Michigan, College of Pharmacy, Department of Clinical Social and Administrative Sciences

November 2013-2025 Scientific Editor, *Pharmacotherapy*

December 2012 – present John Gideon Searle Professor of Clinical and Translational Pharmacy, University of Michigan, College of Pharmacy, Department of Clinical Social and Administrative Sciences

September 2012-present Professor (with tenure), University of Michigan, College of Pharmacy, Department of Clinical Sciences and College of Medicine, Department of Psychiatry, Ann Arbor, Michigan

July 2012 Faculty Member Educational Core, Michigan Institute for Clinical Research (MICHR)

July 2012 Member, Mental Health Initiative, Michigan Institute for Clinical Research (MICHR)

June 2010-June 2022 Savvy Psychopharmacology Department Editor, *Current Psychiatry*

January 2008-present Member, Editorial Board, *Pharmacogenomics & Personalised Medicine*

January 2008-2012 Member Scientific Review/Research Committee, Michigan Institute for Clinical Research (MICHR)

August 2007-2022 Director, Pharmacogenomics Laboratory, University of Michigan College of Pharmacy

July 2007-2022 Member, University of Michigan Comprehensive Depression Center Steering Committee

January 2007-2021 Member, National Alliance for Mentally Ill (NAMI) Scientific Research Council

October 2006 Member, Michigan Metabolomics and Obesity Center (MMOC)

October 2006–present Member, Michigan Diabetes Research and Training Center, University of Michigan, College of Medicine, Ann Arbor, Michigan

August 2006-present Member, Editorial Board, *Pharmacotherapy*

July 2006–present Active Faculty Member, Depression Center. University of Michigan, College of Medicine, Department of Psychiatry, Ann Arbor, Michigan

July 2006–2012 Associate Professor (with tenure), University of Michigan, College of Pharmacy, Department of Clinical Sciences and College of Medicine, Department of Psychiatry, Ann Arbor, Michigan

July 2004–2005 Chair, Clinical Pharmaceutical Sciences Ph.D. program. University of Iowa, College of Pharmacy, Iowa City, Iowa. Clinical and Administrative Pharmacy Division

July 2004–2006 Associate Professor (with tenure), Clinical and Administrative Pharmacy Division, University of Iowa, College of Pharmacy, Iowa City, Iowa

Sept 1999-2006 Adjunct Clinical Instructor University of Iowa, College of Nursing, Iowa City, Iowa

1999–2004 Assistant Professor, University of Iowa, Clinical and Administrative Pharmacy Division, College of Pharmacy, Iowa City, Iowa

1998-2006 Director, Pharmacogenetics Laboratory, Clinical and Administrative Pharmacy Division, University of Iowa, College of Pharmacy, Iowa City, Iowa

1996-1999 Associate, Clinical and Administrative Pharmacy Division, University of Iowa, College of Pharmacy, Iowa City, Iowa

1992-1994 Clinical-Staff pharmacist, part-time to full-time, Fairview Riverside Medical Center Pharmacy, Minneapolis, MN

1988-1992 Pharmacy intern/student, Fairview Riverside Medical Center Pharmacy, Minneapolis, MN

1984-1989 Store clerk/technician, Valley View Drug Store, Edina, MN

**BOARD CERTIFICATION**

November 2006 Psychiatric Pharmacy

November 1997 Psychiatric Pharmacy

**RESEARCH PROJECTS**

***Current Projects (Funded)***

UM1 TR004404 (Lumeng, Mashour, Marsh) 3/15/23-2/28/30 3.0 calendar

NIH $70,980,000

Clinical and Translational Science Award

The major goal is to develop educational and mentoring programs for workforce development for clinical and translational science.

K12 TR004374 (Ellingrod, Robinson) 4/1/23-3-31-28 1.8 calendar

NIH $8,100,000

CTSA K12 Program at the University of Michigan

The major goal of this proposal is to fortify career trajectories with precision preparation, accelerate translation by preparing scholars to best utilize scientific social networks, and to prepare scholars to be versatile communicators who lead effective research teams and become science advocates.

T32 TR004371 (Holinstat, Ellingrod) 4/1/23-3/31/28 1.2 calendar

NIH $2,706,600

CTSA Predoctoral T32 Program at the University of Michigan

The major goal of this proposal is to provide trainees with precision preparation to further their translational research skills.

R25 TR004776 (Woolford, Ellingrod) 12/1/23-11/30/28 0.24 calendar

NIH $540,000

MICHR-Translational Science Immersion (MICHR-TSI)

This R25 CTSA Research Education Grant Program will provide MICHR-TSI participants with translational research experiences and translational science instruction to facilitate precision preparation; Equip MICHR-TSI participants with enhanced scientific social networks to help refine and fuel their translational research engagement; Develop MICHR-TSI participants who are versatile communicators to advance their evolving careers through enhanced dissemination of their work.

T32 TR004764 (Harte, Ellingrod) 12/1/23-11/30/28 0.24 calendar

NIH $1,977,715

CTSA Postdoctoral T32 Program at the University of Michigan

This T32 Postdoctoral Program will Provide postdoctoral trainees with precision preparation for a career in translational science; Strengthen and expand the professional networks of postdoctoral trainees; Prepare postdoctoral trainees to be versatile communicators.

***Previous Support***

U01 (Ellingrod) 2/1/17-3/31/21 0.1 calendar

NIH $669,837

Development, Implementation and AssessMent Of Novel Training in Domain-based Competencies (DIAMOND)

The objective is to develop an online educational portal (DIAMOND portal) for competency-based educational offerings and assessments and to demonstrate integration of this curriculum into CTSA clinical trial education programs at DIAMOND hubs and partner sites in ways that promote the more effective, efficient, and safe execution of clinical trials; allowing for dissemination to a broader audience.

U54 (Ellingrod) 6/1/17-2/28/22 1.8 calendar

NIH $554,700

Michigan Institute for Clinical and Health Research (MICHR) - TL1 Award

The major goal is to develop educational and mentoring programs for workforce development for clinical and translational science.

U54 (Ellingrod) 6/1/17-2/28/22 1.2 calendar

NIH $1,283,758

Michigan Institute for Clinical and Health Research (MICHR) - KL2 Award

The major goal is to develop educational and mentoring programs for workforce development for clinical and translational science.

U54 (Mashour) 6/1/17-2/28/22 4.8 calendar

NIH $89,950

Michigan Institute for Clinical and Health Research (MICHR) - U-award

The major goal is to develop educational and mentoring programs for workforce development for clinical and translational science.

National Institute of Mental Health

05/01/08 – 6/30/19

Role: Role: Principal Investigator

25% effort, $2,500,000 total costs

Antipsychotic and Folate Pharmacogenetics

* The major goal of this study is to examine folate pharmacogenomics in relation to metabolic syndrome, insulin resistance, and endothelial dysfunction from atypical antipsychotic use in schizophrenia and to determine the utility of folate supplementation in attenuation of these complications.

National Center for the Advancement of Translational Science (Mashour)

02/01/2015-05/31/17

Role: Education and Mentoring Faculty Lead

10% effort

Clinical and Translational Science Award

* The major goal is to develop educational and mentoring programs for workforce development for clinical and translational science.

National Institute of Mental Health

06/01/14-05/31/2015

Antipsychotic and Folate Pharmacogenetics” (R01 MH082784) Metabolomics Supplement

Role: Principal Investigator

2.5% Effort, $155,500 total costs

* The purpose of this supplement is to generate metabolomics data that can be used to identify correlational relationships between metabolic profiles and clinical phenotypes of schizophrenia patients treated with AAPs.

National Institute of Mental Health Supplement

06/01/14-05/31/2015

Antipsychotic and Folate Pharmacogenetics” (R01 MH082784) Gender Supplement

Role: Principal Investigator

1.2% Effort, $100,000 total costs

* The purpose of this study is to identify epigenome profile differences in race, age and folate status matched males and female subjects stratified by a metabolic syndrome diagnosis and determine gene-specific methylation differences associated with gender and metabolic syndrome in schizophrenia subjects.

National Institute of Mental Health R01MH090072 (Calarge)

08/01/10-06/30/15

*Investigating the Effects of SSRIs on Bone Health in Adolescents*

Role: Co-Investigator

5% Effort and salary support, $124,086 (UM total costs)

* This investigation examines the pharmacogenomics of the serotonin system in relation to bone density effects of selective serotonin reuptake inhibitor use in adolescents

FDA HHSF223201310164C (Sun)

9/27/13-11/15/15 *Investigation of Release Profiles of Bupropion and Pharmacogenomics of Metabolism Enzymes for*

*Bioequivalence of Generic Bupropion Products in Healthy Volunteers*

Role: Co-Investigator

10% Effort and Salary Support, $185,794

* The objectives of this project are to understand whether and how the release pattern of bupropion HCl products and the genotype of metabolic enzyme affect the bioequivalence conclusions across different dose strengths within one product line due to the saturation of intestinal metabolism.

No number Sunovion (Touchette)

7/1/13-6/30/14

*Beliefs And Attitudes Towards Antipsychotic Use In Patients With Schizophrenia And Bipolar Disorder*

Role: Co-investigator

10% Effort and Salary Support, $21,306 (UM total costs)

* The goal of this study is to describe how psychiatrist and pharmacist beliefs and perceptions regarding the effectiveness, safety, and cost affect the initial choice of atypical antipsychotics and actual use of these agents in the treatment of schizophrenia and bipolar disorder.

National Institute of Mental Health R01 MH082784 (Ellingrod)

05/01/08-01/31/13

*Folate Pharmacogenomics and Risk of Atypical Antipsychotic Metabolic Side Effects*

Role: Principal Investigator

25% Effort and salary support, $1,250,000 (direct costs)/$ 1,859,353 (total costs)

* The goal of this study is to examine folate pharmacogenomics in relation to metabolic syndrome, insulin resistance, and endothelial dysfunction from atypical antipsychotic use in schizophrenia and to determine the utility of folate supplementation in attenuation of these complications.

NIH/NCRR 1 UL1 RR024986 (Clauw/Pienta)

09/17/07-05/31/12

*Clinical and Translational Science Award*

Role: Member of Scientific Review Committee

2007-2010 5% Effort and salary support, 2010-present 2.5% Effort and salary support

* The goal is to review protocols and consult on investigations that use the General Clinical Research Center.

Michigan Institute for Clinical and Health Research (Bleske)

06/01/09–05/31/11

*Role of Vitamin D in Heart Failure (Hemodynamics)*

Role: Investigator

No salary support, $5,000 (total costs)

* The purpose of this investigation is to examine the relationship between genetic variation in the vitamin D receptor and heart failure treatments

National Alliance for Schizophrenia and Depression (Ellingrod)

09/01/07–08/31/10

*Folate pharmacogenomics and metabolic complications from atypical antipsychotic use in bipolar disorder*

Role: Principal Investigator

10% Effort, no salary support, $100,000 (total costs with 8% indirect rate)

* The primary goal of this study is to use explore the relationship between folate metabolism, and antipsychotic associated cardiovascular complications in a bipolar disorder population.

NIMH 5R21MH080968-02 (Calarge)

08/01/08-07/31/10

*Long-term Safety and Genetic Risk Factors of Risperidone Treatment in Youth*

Role: Co-Investigator

7.5% Effort and salary support, $89,000 (total UM costs)

* The goal of this study is to follow-up subejcts who were part of Dr. Calarge’s NARSAD project to determine longer term metabolic complications from antipsychtoic use and pharmacogenomic risk

Michigan Institute for Clinical and Health Research (Stringer)

09/01/07–08/31/08

*Tissue Plasminogen Activator Polymorphisms in ARDS*

Role: Investigator

No salary support, $21,500 (total costs)

* The purpose of this study was to examine the role of genetic variability within the TPA gene and acute respiratory distress syndrome.

Nellie Ball Foundation (Fiedorowicz)

02/01/07–01/31/09

*Cardiovascular Complications of Olanzapine in Affective Disorders*

Role: Consultant

No salary support, $100,000 (total costs)

* The goal of this pilot project is to better characterize the metabolic complications seen from olanzapine use in patients with bipolar depression.

University of Michigan Upjohn/Vahlteich Foundation (Ellingrod)

01/01/07–06/30/08

*Genetic Predictors of Antipsychotic Associated Metabolic Syndrome*

Role: Principal Investigator

No salary support, 40,000 (total costs)

* The goal of this pilot grant is to gather additional pilot data on the relationship of diet and nutrition to the development of metabolic syndrome with atypical antipsychotic use in schizophrenia.

National Alliance for Research in Schizophrenia and Depression (NARSAD) (Calarge)

07/01/05–06/30/07

*The prevalence of long-term risperidone-induced hyperprolactinemia and its effect on sex hormones and BMD*

Role: Investigator

No salary support, $60,000 (total costs)

* The purpose of this study was to examine genetic variablity within dopamine neurotransmitters and the occurance of hyperprolactinemia in children receiving risperidone.

National Institute of Mental Health K08 MH64158 (Ellingrod)

07/01/01–07/31/06

*Genetics of Antipsychotic Metabolism*

Role: Principal Investigator

75-100% Effort and salary support, $525,000 (total costs)

* The purpose of this study was to examine the pharmacogenetics of antipsychotic metabolism and weight gain

University of Iowa, College of Pharmacy, STIR award (Ellingrod)

2004-2006

*Effect of DHEA Administration on the Metabolic Consequences of Atypical Antipsychotic Use in Schizophrenia*

Role: Principal Investigator

10% Effort, no salary support, $10,000 (total costs)

* The purpose of this proposal was to determine the effect of DHEA administration of the metabolic effects of atypical antipsychotic medications in schizophrenia.

University of Iowa, General Clinical Research Center (Fleckenstein)

2004-2006

*An open-label sequential study to evaluate the effect of genetic polymorphisms and orange juice on ivermectin pharmacokinetics in health volunteers*

Role: Investigator

5% Effort, no salary support, $12,760 (total costs)

* This study examined genetic variability within drug transporters and the pharmacokinetics of ivermectin in health volunteers.

National Institute of Mental Health (Schultz)

2003-2005

*Double Blind Placebo Controlled Trial of Ginkgo Biloba Augmentation of Donepezil, Effects on Clinical Outcome and Cerebral Blood Flow*

Role: Investigator

5% Effort, no salary support, $551,250 (total costs)

* This study examined the effect of ginkgo biloba augmentation of donepezil on cerebral blood flow and clinical outcomes.

University of Iowa GCRC Pilot Program (Ellingrod)

2003-2005

*Pharmacogenomics of SSRI Induced Sexual Dysfunction.*

Role: Principal Investigator

10% Effort, no salary support, $10,000 (total costs)

* The objective of this study was to examine the pharmacogenomics of sexual dysfunction associated with antidepressant treatment

Eli Lilly and Company (Ellingrod)

2003-2004

*Reanalysis of Olanzapine dataset for -759C/T 5HR2CR polymorphism.*

Role: Principal Investigator

5% Effort, no salary support, $10,000 (total costs)

* This study reexamined a dataset of olanzapine treatment subjects to determine the role of 5HT2CR variants on weight gain.

Eli Lilly and Company (Perry)

2000-2002

*5HT2A and 5HT2C Receptor Polymorphism Responsible for Predicting Clinical Response to the Antipsychotic Olanzapine*

Role: Co-Principal Investigator

5% Effort, no salary support, $75,000 (total costs)

* This was a clinical trial examining the role of serotonin variants on predicting clinical response to olanzapine.

American College of Clinical Pharmacy (Ellingrod)

1999-2002

*Comparison of Atypical Antipsychotics In Elderly Dementia Patients With Psychosis: Effects on Outcome, Symptom Response, Cognition, and Adverse Medication Effects*

Role: Principal Investigator

10% Effort, no salary support, $10,000 (total costs)

* This study examined the cognitive effects of atypical antipsychotic use in elderly subjects.

American College of Clinical Pharmacy (Perry/Ellingrod)

1995-1996

*Genetic Markers and Drug Metabolism in Children with Tricyclic Induced Arrhythmias*

Role: Principal Investigator, Fellowship

75% Effort, no salary support, $10,000 (total costs)

* This study was part of the ACCP Fellowship program and supported a study examining the relationship between CYP2D6 variability and EKG changes seen in children on tricyclic antidepressants

**PUBLICATIONS**

\* indicates trainee under Dr. Ellingrod’s supervision

***Original Research***

1. Sun D, Macedonia C, Chen Z, Chandrasekaran S, Najarian K, Zhou S, Cernak T, **Ellingrod VL**, Jagadish HV, Marini B, Pai M, Violi A, Rech JC, Wang S, Li Y, Athey B, Omenn GS. Can Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival? J Med Chem. 2024 Sep 26;67(18):16035-16055. doi: 10.1021/acs.jmedchem.4c01684. Epub 2024 Sep 10. PMID: 39253942.
2. Patterson ME, **Ellingrod VL**, Feola DJ, Kunda NK, Mei KC, Oestreich JH, Farrell DF, Giacomini KM. Report of the 2023-2024 AACP Research and Graduate Affairs Committee. Am J Pharm Educ. 2024 Aug;88(8):100745. doi: 10.1016/j.ajpe.2024.100745. Epub 2024 Jun 27. PMID: 38944279.
3. Leung JG, Zhang L, Markota M, **Ellingrod VL**, Gerberi DJ, Bishop JR. A systematic review of clozapine-associated inflammation and related monitoring. Pharmacotherapy. 2023 Dec;43(12):1364-1396. doi: 10.1002/phar.2887. Epub 2023 Oct 31. PMID: 37842767.
4. Ezenwabachili I, Deumic Shultz E, Mills JA, **Ellingrod V**, Calarge CA. Examining Whether Genetic Variants Moderate the Skeletal Effects of Selective Serotonin Reuptake Inhibitors in Older Adolescents and Young Adults. J Child Adolesc Psychopharmacol. 2023 Sep;33(7):260-268. doi: 10.1089/cap.2023.0007. Epub 2023 Aug 9. PMID: 37579130; PMCID: PMC10517324.
5. Kraal AZ, **Ellingrod VL**, Zahodne LB. Depressive Symptoms Longitudinally Mediate the Effect of Hyperglycemia on Memory Decline in Type 2 Diabetes. Diabetes Care. 2023 Sep 1;46(9):1673-1680. doi: 10.2337/dc23-0656. PMID: 37490632; PMCID: PMC10465988.
6. Lee J, Costa-Dookhan K, Panganiban K, MacKenzie N, Treen QC, Chintoh A, Remington G, Müller DJ, Sockalingam S, Gerretsen P, Sanches M, Karnovsky A, Stringer KA, **Ellingrod VL**, Tso IF, Taylor SF, Agarwal SM, Hahn MK, Ward KM. Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study. Front Psychiatry. 2023 Apr 24;14:1169787. doi: 10.3389/fpsyt.2023.1169787. PMID: 37168086; PMCID: PMC10164938.
7. Pasternak AL, Ward K, Irwin M, Okerberg C, Hayes D, Fritsche L, Zoellner S, Virzi J, Choe HM, **Ellingrod V**. Identifying the prevalence of clinically actionable drug-gene interactions in a health system biorepository to guide pharmacogenetics implementation services. Clin Transl Sci. 2023 Feb;16(2):292-304. doi: 10.1111/cts.13449. Epub 2022 Dec 12. PMID: 36510710; PMCID: PMC9926071.
8. Sloat NT, Yashar BM, **Ellingrod VL**, Ward KM. Assessing the impact of pre-test education on patient knowledge, perceptions, and expectations of pharmacogenomic testing to guide antidepressant use. J Genet Couns. 2022 Dec;31(6):1373-1382. doi: 10.1002/jgc4.1612. Epub 2022 Jul 28. PMID: 35900228.
9. Blazy C, **Ellingrod V**, Ward K. Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing Psychotropics. Front Pharmacol. 2022 Jun 24;13:939313. doi: 10.3389/fphar.2022.939313. PMID: 35814245; PMCID: PMC9263441.
10. Eakin BL, Ianni PA, Byks-Jazayeri C, **Ellingrod VL**, Woolford SJ. Reimagining a summer research program during COVID: Strategies for enhancing research workforce diversity. J Clin Transl Sci. 2022 Feb 28;6(1):e37. doi: 10.1017/cts.2022.371. PMID: 35433036; PMCID: PMC9003631.
11. Deumic Shultz E, Mills JA, **Ellingrod VL**, Bishop JR, Calarge CA. Sexual Functioning in Adolescents With Major Depressive Disorder: A Prospective Study. J Clin Psychiatry. 2021 Oct 5;82(6):21m13892. doi: 10.4088/JCP.21m13892. PMID: 34610228.
12. \*Ianni PA, Samuels EM, Eakin BL, Perorazio TE, **Ellingrod VL**. Assessments of Research Competencies for Clinical Investigators: A Systematic Review. Eval Health Prof. 2021 Sep;44(3):268-278. doi: 10.1177/0163278719896392. Epub 2019 Dec 23. PMID: 31867997; PMCID: PMC8274959.
13. Irwin MN, **Ellingrod VL**, Smith MA. Pharmacogenetics of methadone for pain management in palliative care. J Pain Symptom Manage. 2021 Aug 27:S0885-3924(21)00519-4. doi: 10.1016/j.jpainsymman.2021.08.007. Epub ahead of print. PMID: 34461232.
14. \*Kumar P, Kraal AZ, Prawdzik AM, Ringold AE, **Ellingrod V**. Dietary Glutamic Acid, Obesity, and Depressive Symptoms in Patients With Schizophrenia. Front Psychiatry. 2021 Jan 21;11:620097. doi: 10.3389/fpsyt.2020.620097. PMID: 33551881; PMCID: PMC7859478.
15. Lim M, Nascimento TD, Kim DJ, **Ellingrod VL**, DaSilva AF. Aberrant Brain Signal Variability and COMT Genotype in Chronic TMD Patients. J Dent Res. 2021 Jul;100(7):714-722. doi: 10.1177/0022034521994089. Epub 2021 Feb 23. PMID: 33622085; PMCID: PMC8221705.
16. Morris MR, Hoeflich CC, Nutley S, **Ellingrod VL**, Riba MB, Striley CW. Use of psychiatric medication by college students: A decade of data. Pharmacotherapy. 2021 Apr;41(4):350-358. doi: 10.1002/phar.2513. Epub 2021 Mar 5. PMID: 33583071.
17. \*Manzor Mitrzyk B, Plegue MA, Kadri R, Danak SU, Hubbard JD, Kaip EA, Roberson DN, Roy S, Guetterman TC, **Ellingrod VL**, Farris KB, Ruffin Iv MT, Klinkman MS, Buis LR. Pharmacogenomic testing for mental health (Part II): qualitative analysis of early adopter prescriber perceptions. Per Med. 2021 May;18(3):233-240. doi: 10.2217/pme-2020-0084. Epub 2021 Mar 17. PMID: 33728996.
18. \*Manzor Mitrzyk B, Plegue MA, Kadri R, Danak SU, Hubbard JD, Kaip EA, Roberson DN, **Ellingrod VL**, Farris KB, Ruffin MT 4th, Klinkman MS, Buis LR. Pharmacogenomic testing for mental health (Part I): documenting early adopter perceptions of use for eight scenarios. Per Med. 2021 May;18(3):223-232. doi: 10.2217/pme-2020-0083. Epub 2021 Mar 17. PMID: 33728966.
19. Pasternak AL, Ward KM, Ateya MB, Choe HM, Thompson AN, Clark JS, **Ellingrod V**. Establishment of a Pharmacogenetics Service Focused on Optimizing Existing Pharmacogenetic Testing at a Large Academic Health Center. J Pers Med. 2020 Oct 3;10(4):154. doi: 10.3390/jpm10040154. PMID: 33023029; PMCID: PMC7711716.
20. Ianni PA, Samuels EM, Eakin BL, Perorazio TE, **Ellingrod VL**. Assessments of Research Competencies for Clinical Investigators: A Systematic Review. Eval Health Prof. 2019 Dec 23:163278719896392. doi: 10.1177/0163278719896392. Epub ahead of print. PMID: 31867997.
21. Taylor SF, Grove TB, **Ellingrod VL**, Tso IF. The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis. Schizophr Bull. 2019 Oct 24;45(6):1170-1183. doi: 10.1093/schbul/sbz046. PMID: 31150555; PMCID: PMC6811817.
22. Nascimento TD, Yang N, Salman D, Jassar H, Kaciroti N, Bellile E, Danciu T, Koeppe R, Stohler C, Zubieta JK, **Ellingrod V**, DaSilva AF. µ-Opioid Activity in Chronic TMD Pain Is Associated with COMT Polymorphism. J Dent Res. 2019 Nov;98(12):1324-1331. doi: 10.1177/0022034519871938. Epub 2019 Sep 6. PMID: 31490699; PMCID: PMC6806132.
23. \*Manzor Mitrzyk B, Kadri R, Farris KB, **Ellingrod VL**, Klinkman MS, Ruffin Iv MT, Plegue MA, Buis LR. Using Pharmacogenomic Testing in Primary Care: Protocol for a Pilot Randomized Controlled Study. JMIR Res Protoc. 2019 Aug 19;8(8):e13848. doi:10.2196/13848. PubMed PMID: 31429417.
24. \*Kraal AZ, \*Moll AC, \*Arvanitis NR, \*Ward KM, \*Dougherty RJ, \*Grove TB, \*Burghardt KJ, **Ellingrod VL**. Metabolic syndrome is negatively associated with cognition among endothelial nitric oxide synthase (eNOS)- 786C carriers in schizophrenia-spectrum disorders. J Psychiatr Res. 2019 Oct;117:142-147. doi: 10.1016/j.jpsychires.2019.07.006. Epub 2019 Jul 26. PubMed PMID: 31421598.
25. Touchette DR, Gor D, Sharma D, Chennault RR, Ng-Mak DS, Rajagopalan K, **Ellingrod V**. Psychiatrist and Psychiatric Pharmacists Beliefs and Preferences for Atypical Antipsychotic Treatments in Patients With Schizophrenia and Bipolar Disorders. J Pharm Pract. 2019 Jun 25:897190019854566. doi: 10.1177/0897190019854566. [Epub ahead of print] PubMed PMID: 31238761.
26. Hornung CA, Ianni PA, Jones CT, Samuels EM, **Ellingrod VL**; DIAMOND Investigators. Indices of Clinical Research Coordinators' Competence. J Clin Transl Sci. 2019 Jun;3(2-3):75-81. doi: 10.1017/cts.2019.381. Epub 2019 Jul 24. PMID: 31552144; PMCID: PMC6759060.
27. Byks-Jazayeri C, Samuels E, Anderson EW, **Ellingrod VL**. Implementing and measuring the impact of a clinical and translational research mentor recognition program. J Clin Transl Sci. 2018 Oct;2(5):312-320. doi: 10.1017/cts.2018.329. PubMed PMID: 30828473; PubMed Central PMCID: PMC6390404.
28. \*Kraal AZ, \*Arvanitis NR, \*Jaeger AP, **Ellingrod VL**. Could Dietary Glutamate Play a Role in Psychiatric Distress? Neuropsychobiology. 2019 Jan 30:1-7. doi: 10.1159/000496294. [Epub ahead of print] Review. PubMed PMID: 30699435; PubMed Central PMCID: PMC6667320.
29. \*Flowers SA, Baxter NT, Ward KM, Kraal AZ, McInnis MG, Schmidt TM, **Ellingrod VL**. Effects of Atypical Antipsychotic Treatment and Resistant Starch Supplementation on Gut Microbiome Composition in a Cohort of Patients with Bipolar Disorder or Schizophrenia. Pharmacotherapy. 2019 Jan 8. doi: 10.1002/phar.2214. [Epub ahead of print] PubMed PMID: 30620405.
30. \*Kim E, Ndege PK, Jackson E, Clauw DJ, Ellingrod VL. Patient perspectives on medication self-management in rural Kenya: a cross-sectional survey. Int J Qual Health Care. 2019 Jun 1;31(5):353-358. doi: 10.1093/intqhc/mzy187. PMID: 30256956.
31. Burghardt KJ, Goodrich JM, Lines BN, **Ellingrod VL**. The Influence of Metabolic Syndrome and Sex on the DNA Methylome in Schizophrenia. Int J Genomics. 2018 Apr 3;2018:8076397. doi: 10.1155/2018/8076397. eCollection 2018. PubMed PMID: 29850476; PubMed Central PMCID: PMC5903198.
32. Grove TB, Yao B, Mueller SA, McLaughlin M, **Ellingrod VL**, McInnis MG, Taylor SF, Deldin PJ, Tso IF. A Bayesian model comparison approach to test the specificity of visual integration impairment in schizophrenia or psychosis. Psychiatry Res. 2018 Jul;265:271-278. doi: 10.1016/j.psychres.2018.04.061. Epub 2018 May 7. PubMed PMID: 29768190.
33. \*Ward KM, Yeoman L, McHugh C, Kraal AZ, Flowers SA, Rothberg AE, Karnovsky A, Das AK, **Ellingrod VL**, Stringer KA. Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia. Pharmacotherapy. 2018 Jun;38(6):638-650. doi: 10.1002/phar.2119. PubMed PMID: 29722909; PubMed Central PMCID: PMC6014920.
34. Yao B, Mueller SA, Grove TB, McLaughlin M, Thakkar K, **Ellingrod V**, McInnis MG, Taylor SF, Deldin PJ, Tso IF. Eye gaze perception in bipolar disorder: Self-referential bias but intact perceptual sensitivity. Bipolar Disord. 2018 Feb;20(1):60-69. doi: 10.1111/bdi.12564. Epub 2017 Nov 23. PubMed PMID: 29168603; PubMed Central PMCID: PMC5807101.
35. Pasternak AL, Ward KM, Luzum JA, **Ellingrod VL**, Hertz DL. Germline genetic variants with implications for disease risk and therapeutic outcomes. Physiol Genomics. 2017 Oct 1;49(10):567-581. doi: 10.1152/physiolgenomics.00035.2017. Epub 2017 Sep 8. Review. PubMed PMID: 28887371; PubMed Central PMCID: PMC5668651.
36. Bishop JR, **Ellingrod VL**. Precision Pharmacotherapy Enables Precision Medicine. Pharmacotherapy. 2017 Sep;37(9):985-987. doi: 10.1002/phar.1998. Epub 2017 Aug 23. PubMed PMID: 28836287.
37. Hertz DL, Luzum JA, Pasternak AL, Ward KM, Zhu HJ, Rae JM, **Ellingrod VL.** Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy. Pharmacogenomics. 2017 Jul 26. doi: 10.2217/pgs-2017-0107. [Epub ahead of print] PubMed PMID: 28745551.
38. \*Kraal AZ, Ward KM, **Ellingrod VL**. Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders. Psychopharmacol Bull. 2017 May 15;47(2):8-21. PubMed PMID: 28626268; PubMed Central PMCID: PMC5472174.
39. Connarn JN, Flowers S, Kelly M, Luo R, Ward KM, Harrington G, Moncion I, Kamali M, McInnis M, Feng MR, **Ellingrod V**, Babiskin A, Zhang X, Sun D. Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers. AAPS J. 2017 Sep;19(5):1513-1522. doi: 10.1208/s12248-017-0102-8. Epub 2017 Jul 6. PubMed PMID: 28685396.
40. Eddington Chair ND, Aubé J, Das SK, **Ellingrod VL**, Hansen R, Madhavan SS, Monks TJ, Morris ME, Lakoski Staff Liaison JM. Report of the 2014-2016 AACP Research and Graduate Affairs Committee. Am J Pharm Educ. 2016 Nov 25;80(9):S21. doi: 10.5688/ajpe809S21. PubMed PMID: 28090116; PubMed Central PMCID: PMC5222741.
41. \*Flowers SA, Evans SJ, Ward KM, McInnis MG, **Ellingrod VL**. Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort. Pharmacotherapy. 2017 Mar;37(3):261-267. doi: 10.1002/phar.1890. Epub 2017 Feb 20. PubMed PMID: 28035686.
42. Hirasawa-Fujita M, Bly MJ, **Ellingrod VL**, Dalack GW, Domino EF. Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar Disorder. Clin Schizophr Relat Psychoses. Spring 2017;11(1):39-48. doi: 10.3371/1935-1232-11.1.39. PubMed PMID: 28548579; PubMed Central PMCID: PMC4366347.
43. Hicks JK, Sangkuhl K, Swen JJ, **Ellingrod V**L, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2016 Dec 20. doi: 10.1002/cpt.597. [Epub ahead of print] PubMed PMID: 27997040; PubMed Central PMCID: PMC5478479.
44. Evans SJ, Bassis CM, Hein R, Assari S, Flowers SA, Kelly MB, Young VB, **Ellingrod VL**, McInnis MG. The gut microbiome composition associates with bipolar disorder and illness severity. J Psychiatr Res. 2017 Apr;87:23-29. doi: 10.1016/j.jpsychires.2016.12.007. Epub 2016 Dec 10. PubMed PMID: 27988330; PubMed Central PMCID: PMC5336480.
45. \*Ward KM, Kraal AZ, Flowers SA, **Ellingrod VL**. Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia. Pharmacotherapy. 2017 Sep;37(9):1122-1130. doi: 10.1002/phar.1968. Epub 2017 Aug 2. PubMed PMID: 28605058; PubMed Central PMCID: PMC5600660.
46. \*Grove TB, Burghardt KJ, Kraal AZ, Dougherty RJ, Taylor SF, **Ellingrod VL**. Oxytocin Receptor (OXTR) Methylation and Cognition in Psychotic Disorders. MolNeuropsychiatry. 2016 Oct;2(3):151-160. PubMed PMID: 27867940.
47. Connarn JN, Luo R, Windak J, Zhang X, Babiskin A, Kelly M, Harrington G, **Ellingrod VL**, Kamali M, McInnis M, Sun D. Identification of Non-Reported Bupropion Metabolites in Human Plasma. Biopharm Drug Dispos. 2016 Oct 10. doi:10.1002/bdd.2046. [Epub ahead of print] PubMed PMID: 27723114.
48. \*Burghardt KJ, Goodrich JM, Dolinoy DC, **Ellingrod VL**. Gene-specific DNA methylation may mediate atypical antipsychotic-induced insulin resistance. Bipolar Disord. 2016 Aug;18(5):423-32. doi: 10.1111/bdi.12422. PubMed PMID:27542345.
49. \*Grove TB, Tso IF, Chun J, Mueller SA, Taylor SF, **Ellingrod VL**, McInnis MG, Deldin PJ. Negative affect predicts social functioning across schizophrenia and bipolar disorder: Findings from an integrated data analysis. Psychiatry Res. 2016 Sep 30;243:198-206. doi: 10.1016/j.psychres.2016.06.031. PubMed PMID: 27416540; PubMed Central PMCID: PMC5014676.
50. \*Flowers SA, Ryan KA, Lai Z, McInnis MG, **Ellingrod VL**. Interaction between COMTrs5993883 and second generation antipsychotics is linked to decreases in verbal cognition and cognitive control in bipolar disorder. BMC Psychol. 2016 Apr 2;4:14. doi: 10.1186/s40359-016-0118-3. PubMed PMID: 27039372; PubMed CentralPMCID: PMC4818866.
51. \*Burghardt KJ, Evans SJ, Wiese KM, **Ellingrod VL**. An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar Disorder. Clin Transl Sci. 2015 Oct;8(5):432-40. doi: 10.1111/cts.12324. Epub 2015 Aug 27. PubMed PMID: 26314700; PubMed Central PMCID: PMC4626284.
52. Fiedorowicz JG, **Ellingrod VL**, Kaplan MJ, Sen S. The development of depressive symptoms during medical internship stress predicts worsening vascular function. J Psychosom Res. 2015 Sep;79(3):243-5. doi: 10.1016/j.jpsychores.2015.06.004. Epub 2015 Jun 18. PubMed PMID: 26115588; PubMed Central PMCID: PMC4522220.
53. \*Burghardt KJ, Goodrich JM, Dolinoy DC, **Ellingrod VL**. DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder. Epigenomics.2015;7(3):343-52. doi: 10.2217/epi.15.5. PubMed PMID: 26077424; PubMed Central PMCID: PMC4501018.
54. \*Grove T, Taylor S, Dalack G, **Ellingrod V**. Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders. Schizophr Res. 2015 May;164(1-3):115-21. doi: 10.1016/j.schres.2015.02.006. Epub 2015 Feb 23. PubMed PMID: 25728832; PubMed Central PMCID: PMC4409513.
55. Hirasawa-Fujita M, Bly MJ, **Ellingrod VL**, Dalack GW, Domino EF. Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar Disorder. Clin Schizophr Relat Psychoses. 2014 Jun 20:1-27. [Epub ahead of print]PubMed PMID: 24951719.
56. O'Malley M, King AN, Conte M, **Ellingrod VL**, Ramnath N. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. J Thorac Oncol. 2014 Jul;9(7):917-26. doi: 10.1097/JTO.0000000000000191. PubMed PMID: 24926542.
57. Del Castillo N, Zimmerman M B, Tyler B, **Ellingrod VL**, Calarge C. 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment. Clin Pharmacol Biopharm. 2013 Jun29;2(2):110. PubMed PMID: 24772381; PubMed Central PMCID: PMC3997261.
58. Bleske BE, Remington TL, Wells TD, Dorsch MP, Guthrie SK, Stumpf JL, Alaniz MC, **Ellingrod VL**, Tingen JM. Team-based learning to improve learning outcomes in a therapeutics course sequence. Am J Pharm Educ. 2014 Feb 12;78(1):13. doi: 10.5688/ajpe78113. PubMed PMID: 24558281; PubMed Central PMCID: PMC3930237.
59. Dorsch MP, Nemerovski CW, **Ellingrod VL**, Cowger JA, Dyke DB, Koelling TM, Wu AH, Aaronson KD, Simpson RU, Bleske BE. Vitamin D Receptor Genetics on Extracellular Matrix Biomarkers and Hemodynamics in Systolic Heart Failure. J Cardiovasc Pharmacol Ther. 2014 Feb 4. [Epub ahead of print] PubMed PMID:24500905.
60. \*Burghardt KJ, Gardner KN, Johnson JW, **Ellingrod VL**. Fatty Acid desaturase gene polymorphisms and metabolic measures in schizophrenia and bipolar patients taking antipsychotics. Cardiovasc Psychiatry Neurol. 2013;2013:596945. doi:10.1155/2013/596945. Epub 2013 Dec 21. PubMed PMID: 24455201; PMCID: PMC3880735.
61. \*Burghardt K, Grove T, **Ellingrod V**. Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia. J Psychopharmacol. 2013 Dec 17. [Epub ahead of print] PubMed PMID: 24346810.
62. \*Bly MJ, Taylor SF, Dalack G, Pop-Busui R, Burghardt KJ, Evans SJ, McInnis MI, Grove TB, Brook RD, Zöllner SK, **Ellingrod VL**. Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. Bipolar Disord. 2013 Dec 13. doi:10.1111/bdi.12160. [Epub ahead of print] PubMed PMID: 24330321.
63. \*Vassas TJ, Burghardt KJ, **Ellingrod VL**. Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics. Pharmacogenomics. 2014 Jan;15(1):61-7. doi: 10.2217/pgs.13.157. PubMed PMID: 24329191.
64. Parker RB, **Ellingrod V**, DiPiro JT, Bauman JL, Blouin RA, Welage LS. Preparing clinical pharmacy scientists for careers in clinical/translational research: can we meet the challenge?: ACCP Research Affairs Committee Commentary.Pharmacotherapy. 2013 Dec;33(12):e337-46. doi: 10.1002/phar.1348. Epub 2013 Sep 30. PubMed PMID: 24114730.
65. Prossin AR, Zalcman SS, Evans SJ, McInnis MG, **Ellingrod VL**. A pilot study investigating tumor necrosis factor-α as a potential intervening variable of atypical antipsychotic-associated metabolic syndrome in bipolar disorder. Ther Drug Monit. 2013 Apr;35(2):194-202. doi: 10.1097/FTD.0b013e31827e18d2. PubMed PMID: 23503445; PMCID: PMC3623939.
66. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, **Ellingrod VL**, Skaar TC, Müller DJ, Gaedigk A, Stingl JC; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013 May;93(5):402-8. doi: 10.1038/clpt.2013.2. Epub 2013 Jan 16. Review. PubMed PMID: 23486447; PubMed Central PMCID: PMC3689226.
67. \*Bly MJ, Bishop JR, Thomas KL, **Ellingrod VL**. P-glycoprotein (PGP) polymorphisms and sexual dysfunction in female patients with depression and SSRI-associated sexual side effects. J Sex Marital Ther. 2013;39(3):280-8. doi:10.1080/0092623X.2011.615896. Epub 2013 Jan 28. PubMed PMID: 23356581; PMCID: PMC3807815.
68. Yuan ST, **Ellingrod VL**, Schipper M, Stringer KA, Cai X, Hayman JA, Yu J, Lawrence TS, Kong FM. Genetic variations in TGFβ1, tPA, and ACE and radiation-induced thoracic toxicities in patients with non-small-cell lung cancer. J Thorac Oncol. 2013 Feb;8(2):208-13. doi: 10.1097/JTO.0b013e318274592e. PubMed PMID: 23334061; PubMed Central PMCID: PMC3646090.
69. Ramnath N, Daignault-Newton S, Dy GK, Muindi JR, Adjei A, **Ellingrod VL**, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Troeschel S, Johnson CS, Trump DL. A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2013 May;71(5):1173-82. doi:. PubMed PMID: 23435876; PMC3637851.
70. Evans SJ, Kamali M, Prossin AR, Harrington GJ, **Ellingrod VL**, McInnis MG, Burant CF. Association of plasma omega-3 and omega-6 lipids with burden of disease measures in bipolar subjects. J Psychiatr Res. 2012 Aug 9. [Epub ahead of print] PubMed PMID: 22884424.
71. Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, **Ellingrod VL**, Haynes WG.Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Curr Psychiatry Rev. 2012 Feb1;8(1):25-36. PubMed PMID: 22712004; PubMed Central PMCID: PMC3375952.
72. \*Burghardt KJ, Pilsner JR, Bly MJ, **Ellingrod VL**. DNA methylation in schizophrenia subjects: gender and MTHFR 677C/T genotype differences. Epigenomics. 2012 Jun;4(3):261-8. PubMed PMID: 22690662; PubMed Central PMCID:PMC3392683.
73. Bishop JR, Chae SS, Patel S, Moline J, **Ellingrod VL**. Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction. Psychiatry Res. 2012 Apr 23. [Epub ahead of print] PubMed PMID: 22534499.
74. Lott SA, Burghardt PR, Burghardt KJ, Bly MJ, Grove TB, **Ellingrod VL**. The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia. Pharmacogenomics J. 2012 Mar 6. doi: 10.1038/tpj.2012.6. [Epub ahead of print]PubMed PMID: 22391769.
75. Evans SJ, Prossin AR, Harrington GJ, Kamali M, **Ellingrod VL**, Burant CF, McInnis MG. Fats and Factors: Lipid Profiles. Associate with Personality Factors and Suicidal History in Bipolar Subjects. PLoS One. 2012;7(1):e29297. Epub 2012 Jan 13. PubMed PMID: 22253709; PubMed Central PMCID: PMC3258247.
76. **Ellingrod VL**, Taylor SF, Dalack G, Grove TB, Bly MJ, Brook RD, Zöllner SK, Pop-Busui R. Risk Factors Associated with Metabolic Syndrome in Bipolar and Schizophrenia Subjects Treated With Antipsychotics: The Role of Folate Pharmacogenetics. J Clin Psychopharmacol. 2012 Apr;32(2):261-5. PubMed PMID: 22370993.
77. Fiedorowicz JG, Coryell WH, Akhter A, **Ellingrod VL**. Chryptochrome 2 Variants, Chronicity, and Seasonality of Mood Disorders. Psychiatric Genetics (in press).
78. \*Bly MJ, Thomas KLH, **Ellingrod VL**, Bishop JR. P-glycoprotein (ABCB1) Polymorphisms and Sexual Dysfunction in Patients with Depression and SSRI-Associated Sexual Side Effects. The Journal of Sex and Marital Therapy (in press)
79. Houston J, Kohler J, Bishop JR, **Ellingrod VL**, Ostbye KM, Zhao F, Conley R, Hoffmann VP, Fijal B. Pharmacogenomic Associations with Weight Gain in Olanzapine Treatment of Patients without Schizophrenia. Psychiatry Res. 2011 May 15;187(1-2):74-9. Epub 2010 Nov 20.
80. Prabhakar M, Haynes WG, Coryell WH, Chrischilles EA, Miller DD, Arndt S, **Ellingrod VL**, Warren L, Fiedorowicz JG. Clinical Variables Impacting Prescribing of Olanzapine, Quetiapine, and Risperidone. Pharmacotherapy 2011; 31(8): 806-812
81. **Ellingrod VL**, Taylor SF, Brook RD, Evans SJ, Zöllner SK, Grove TB, Gardner KM, Bly MJ, Pop-Busui R, Dalack G. Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs). Schizophr Res. 2011 Apr 18. [Epub ahead of print] PubMed PMID: 21504842, PMCID: 3139795
82. Houston J, Dharia S, Bishop JR, **Ellingrod VL**, Fijal B, Jacobson JG, Hoffmann VP. Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry Res. 2011 May 15;187(1-2):74-9. Epub 2010 Nov 20. PubMed PMID: 21095016.
83. Bishop JR, Miller DD, **Ellingrod VL**, Holman T. Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia. Hum Psychopharmacol. 2011 Feb 23. doi: 10.1002/hup.1163. [Epub ahead of print] PubMed PMID: 21344500.
84. Kang H, Smith M, Buckwalter KC, **Ellingrod V**, Schultz SK. Anxiety, depression, and cognitive impairment in dementia-specific and traditional assisted living. J Gerontol Nurs. 2010 Jan;36(1):18-30; quiz 32-3. doi: 10.3928/00989134-20091204-01. Epub 2010 Jan 12. PubMed PMID: 20047249; PubMed Central PMCID: PMC3005246.
85. \*Thomas KL, **Ellingrod VL**, Bishop JR, Keiser MJ. A Pilot Study of the Pharmacodynamic Impact of SSRI Drug Selection and Beta-1 Receptor Genotype (ADRB1) on Cardiac Vital Signs in Depressed Patients: A Novel Pharmacogenetic Approach. Psychopharmacol Bull. 2010;43(1):11-22. PubMed PMID: 20581797.
86. Bishop JR, **Ellingrod VL**, Akroush M, Moline J (2009). The Association of Serotonin Transporter Genotypes and Selective Serotonin Reuptake Inhibitor (SSRI) Associated Sexual Side Effects: Possible Relationship to Oral Contraceptives Hum Psychopharmacol;24(3):207-15. PMID: 19204908
87. Calarge C, **Ellingrod VL**, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte J(2009). Variants of the Dopamine Receptor and Risperidone-Induced Hyperprolactinemia in Children and Adolescents Pharmacogenet Genomics;19(5):373-82.
88. Calarge C, **Ellingrod VL**, Zimmerman B, Acion L, Sivitz W, Schlechte J. Leptin promoter -2548A/G variants predict antipsychotic-associated weight gain in children Psychiatr Genet. 2009 Dec;19(6):320-7. PubMed PMID: 19873684; PubMed Central PMCID: PMC2919234.
89. **Ellingrod VL**, Miller DD, Taylor F (2008). Metabolic Syndrome and Insulin Resistance in Schizophrenia Patients Receiving Antipsychotics Genotyped for the Methylenetetrahydrofolate Reductase (MTHFR) 677CTand 1298AC Polymorphism. Schizophrenia Research 98(1-3):47-54.
90. Smith M, Buckwalter KC, Kang H, Schultz SK, **Ellingrod VL** (2008). Tales from the field. What the nursing research textbooks will not tell you. Applied Nursing Research; 21: 232-236.
91. Smith M, Buckwalter KC, Kang H, Schultz SK, **Ellingrod VL** (2008). Dementia-Specific Assisted Living: Clinical Factors and Psychotropic Medication Use. Journal of the American Psychiatric Nurses Association; 14: 39-49.
92. Smith M, Buckwalter KC, Kang H, Schultz SK, **Ellingrod VL** (2008). Dementia Care in Assisted Living: Needs and Challenges. Issues Ment Health Nurs.;29(8):817-38.
93. \*Bishop JR, Wang K, Moline J, **Ellingrod VL** (2007).Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatric Genetics;17(6):358
94. \*Worsham J, **Ellingrod VL**, Bishop JR (2007). Review of sexual dysfunction associated with antidepressant use. Journal of the College of Psychiatric and Neurologic Pharmacists. Available at: http://cpnp.org/\_docs/news/20070126.pdf
95. **Ellingrod VL**, Bishop JR, Moline J, Miller D: Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia (2007). Psychopharmacology Bulletin; 40(1): 57-62.
96. Fiedorowicz JG, MoserDJ, HynesSM, BeglingerLJ, SchultzSK, and **EllingrodVL** (2007). LA Allelic Heterozygosity of the 5HTTLPR Polymorphism is Associated with Higher Cognitive Function and Lower Interpersonal Sensitivity. Psychiatric Genetics;17(1):3-4.
97. \*Lin Ying-Chi, **Ellingrod VL**, Bishop JR, Moline J, Miller DD (2006). P-glycoprotein polymorphisms and olanzapine response in patients with schizophrenia. Ther Drug Monit; 28: 668-672.
98. \*Bishop JR, **Ellingrod VL**, Moline J, Schultz SK (2006). Association between polymorphisms of the G-protein beta subunit (GNB3) and serotonin-2A receptor polymorphisms and sexual dysfunction in persons treated with an SSRI for depression. Neuropsychopharmacology;31(10):2281-2288.
99. \*Bishop JR, **Ellingrod VL**, Moline J, Miller D (2006): Association analysis of G-protein Beta3 Subunit Gene (C825T) polymorphisms with clinical response or olanzapine or olanzapine related weight gain in persons with schizophrenia. Med Sci Mon; 12(2):BR47-50.
100. Schultz SK, Moser D, Bishop JR, **Ellingrod VL** (2005). Phobic anxiety in late-life in relationship to cognition and 5HTTLPR polymorphism. Psychiatric Genetics;15(4):305-6.
101. \*Bishop JR, **Ellingrod VL**, Moline J, Miller D (2005). Association of polymorphisms in the *GRM3* gene response to olanzapine. Schizophrenia Research; 77(2-3):253-60.
102. Perry PJ, Argo TR, Carnahan RM, Lund BC, Holman TL, **Ellingrod VL**, Miller D (2005). The Association of Weight Gain and Olanzapine Plasma Concentrations. Journal of Clinical Psychopharmacology; 25(3):250-254.
103. **Ellingrod VL**, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F, Holman T, Miller DD (2005). Weight Gain Associated With The -759 C/T Polymorphism of the 5HT2C Receptor And Olanzapine. Am J Med Genetics: 134B; 76-78.
104. Miller DD, **Ellingrod VL**, Holman TL, Buckley PF, Arndt S (2005). Weight Gain Associated with the -759 C/T Polymorphism of the 5HT2C Receptor and Clozapine. Am J Med Genetics: 133B; 97-100.
105. Min, DI, **Ellingrod VL,** McLeod H, Marsh S (2004). Association of CYP3A5\*3 Polymorphism with Cyclosporine Pharmacokinetics in Healthy Subjects. Therapeutic Drug Monitoring; 26: 524-528.
106. Weissman AM, Hartz AJ, Bentler S, Donohue M, **Ellingrod V,** Wisner KL (2004). Meta-analysis of antidepressant levels in lactating mothers, breast milk and nursing infants. American Journal of Psychiatry. 161(6):1066-78.
107. **Ellingrod** VL. Miller D. Ringold JC. Perry PJ (2004). Distribution of the serotonin 2C (5HT2C) receptor gene -759C/T polymorphism in patients with schizophrenia and normal controls. Psychiatric Genetics. 14(2):93-5.
108. **Ellingrod VL**, Perry PJ, Stille KA, Lund BL, Fleming F, Holman T, Miller DD (2003) 5HT2A Receptor Promoter Polymorphism, -1438G/A And Negative Symptom Response To Olanzapine In Schizophrenia. Psychopharmacology Bulletin; 37: 109-112.
109. Schultz SK, **Ellingrod V**, Turvey C, Moser D, Kutscher E, Arndt S (2002). Psychiatric Symptoms Among Nursing Home Residents:  Relationships between Symptoms, Cognition and Daily Functioning. Am J Psychiatry; 160(3): 582-4.
110. **Ellingrod VL**, Perry PJ, Lund BL , Bever -Stille KA, Fleming F, Holman TL, Miller DD (2002). 5-HT2A and 5-HT2C receptor polymorphism responsible for predicting clinical response to the antipsychotic agent olanzapine. J Clin Psychopharmacol; 22: 554-60.
111. **Ellingrod VL**, Schultz SK, Arndt SA. (2002) Cigarette smoking, CYP2D6, and abnormal movements. Pharmacotherapy; 22(11); 1416-1419.
112. Min DI and **Ellingrod VL** (2002). The C3435T mutation in exon 26 of the human *MDR1* gene and cyclosporine pharmacokinetics in healthy subjects. Therapeutic Drug Monitoring; 24: 400-404.
113. **Ellingrod VL**, Miller DD, Schultz SK, Wehring H, Arndt S (2002). CYP2D6 Polymorphisms And Atypical Antipsychotic Weight Gain. Psychiatric Genetics; 12: 55-581.
114. **Ellingrod VL,** Schultz SK, Ekstam-Smith K, Kutscher E, Arndt S, Turvey C (2002).Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. Pharmacotherapy; 22: 1-5.
115. Turvey C, Schultz SK, Arndt SA, **Ellingrod VL,** Wallace R, Herzog R (2001). Caregiver reports of hallucinations and delusions in elderly aged 70 and older. Intl Psychogeriatrics; 13: 241-9.
116. Schultz SK, **Ellingrod V**, Fleming FW, Andreasen NC (2001) The Association between risk factors for tardive dyskinesia and phenylalanine-induced abnormal movements in schizophrenia. Human Psychopharmacology; 16: 273-277.
117. **Ellingrod VL,** Schultz, SK, and Arndt S (2000). Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatric Genetics; 10: 9-11.
118. Van Dyke DC, **Ellingrod VL,** Berg MJ, Niebyl JR, Sherbondy AL, and Trembath DG (2000). Pharmacogenetic screening for susceptibility to fetal malformation in women: a reality for the future? Obstetrics and Gynecological Survey. Ann Pharmcother;34:639-645.
119. Long, TD, **Ellingrod VL**, Kathol RG, Christensen LE, Resch DS, and Perry PJ (2000). Lack of menstrual cycle effects on hypothalamic-pituitary-adrenal axis response to insulin-induced hypoglycemia. Clinical Endocrinology; 52 (6): 781-787.
120. Anfinson T, McKay S, Engel S, Locke C, Feldmann J, **Ellingrod V**, DeWitt B, Olson J, Caruth M (1999). Interdisciplinary team roles in a combined medical psychiatry treatment program. Primary Psychiatry; 6(7): 80-85
121. Yates WR, Perry PJ, MacIndoe JH, Holman T, **Ellingrod V** (1999): Psychosexual effects of three doses of testosterone cycling in normal men. Biological Psychiatry; 45: 254-260.
122. **Ellingrod VL**, Perry PJ, Yates WR, MacIndoe JH, Watson G, Arndt S, and Holman TL (1997). The effects of anabolic steroids on driving performance as assessed by the Iowa driver simulator. Am J of Drug and Alcohol Abuse; 23: 623-636.
123. MacIndoe JH, Perry PJ, Yates WR, Holman TL, **Ellingrod VL**, Scott SD (1997). Testosterone suppression of the HPT axis. Journal of Investigational Medicine; 45: 441-447.

***Reviews***

1. Pasternak AL, Ward KM, Luzum JA, **Ellingrod VL**, Hertz DL. Germline genetic variants with implications for disease risk and therapeutic outcomes. Physiol Genomics. 2017 Oct 1;49(10):567-581. doi: 10.1152/physiolgenomics.00035.2017.Epub 2017 Sep 8. Review. PubMed PMID: 28887371; PubMed Central PMCID: PMC5668651.
2. \*Flowers SA, **Ellingrod VL**. The Microbiome in Mental Health: Potential Contribution of Gut Microbiota in Disease and Pharmacotherapy Management. Pharmacotherapy. 2015 Oct;35(10):910-6. doi: 10.1002/phar.1640. Review. PubMedPMID: 26497477.
3. **Ellingrod VL**. PharmGenEd™ Psychiatry I Module: Depression. <http://www.scivee.tv/node/25243>. Released on October 22, 2010 (275 views)
4. **Ellingrod VL**. Introduction to the CPNP 2010 Annual Meeting Poster Abstracts. J Pharm Pract. 2010 Apr;23(2):148. PubMed PMID: 21507810.
5. Thomas KL, **Ellingrod VL**. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy. 2009 Jul;29(7):822-31. Review. PubMed PMID: 19558256.
6. Bostwick JR, Guthrie SK, **Ellingrod VL** (2009). Antipsychotic-Induced Hyperprolactinemia. Pharmacotherapy;29(1):64-73.
7. **Ellingrod VL** and Moline J (2007). Incorporating Pharmacogenomics into Practice. Journal of Pharmacy Practice; 20: 277-282.
8. Leckband SG, Bishop JR, **Ellingrod VL** (2007). Pharmacogenomics in Psychiatry. Journal of Pharmacy Practice;20: 252-264.
9. **Ellingrod VL** and Moline J (2007). Introduction to Pharmacogenomics. Journal of Pharmacy Practice;20: 203-205.
10. \*Bishop JR and **Ellingrod VL** (2007). Metabotropic glutamate receptors as pharmacogenetic candidate genes in studies of current and future antipsychotic agents in schizophrenia. Current Pharmacogenetics; 5: 21-30.
11. \*Bishop JR. **Ellingrod VL** (2004). Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response. Pharmacogenomics. 5(5):463-77.
12. **Ellingrod VL** (1998). A Pharmacotherapy Review of Primary Obsessive Compulsive Disorder Literature. Pharmacotherapy; 18: 936-960.
13. **Ellingrod VL** and Perry PJ, Nefazodone: A new antidepressant, Am J Health-Syst Pharm 1995; 52: 2799-812.
14. **Ellingrod VL** and Perry PJ, Venlafaxine: A heterocyclic antidepressant, Am J Hosp Pharm 1994; 51: 3033-46.

***Book and Book Chapters***

1. Schwinghammer TL, DiPiro JT, **Ellingrod VL**, DiPiro CV (2023). Pharmacotherapy Handbook, 12th edition, McGraw Hill, Manhattan, NY.
2. DiPiro J, Yee G, Posey M, Haines S, Nolin T, and **Ellingrod VL** (2022). Pharmacotherapy a Pathophysiological Approach, 12th edition, McGraw Hill, Manhattan, NY.
3. Schwinghammer TL, DiPiro JT, **Ellingrod VL**, DiPiro CV (2020). Pharmacotherapy Handbook, 11th edition, McGraw Hill, Manhattan, NY.
4. DiPiro J, Yee G, Posey M, Haines S, Nolin T, and **Ellingrod V** (2019). Pharmacotherapy a Pathophysiological Approach, 11th edition, McGraw Hill, Manhattan, NY.
5. Humma LM, **Ellingrod VL**, Kolesar JM (2012). Pharmacogenomics handbook. Lexi-Comp. Hudson, Ohio.
6. **Ellingrod VL**, Bishop JR, Thomas K (2010). Pharmacogenomics of Psychiatry. In:Pharmacogenomics:  Applications to Patient Care. ACCP, Kansas City.
7. Humma LM, **Ellingrod VL**, Kolesar JM (2005). Pharmacogenomics handbook. Lexi-Comp. Hudson, Ohio.
8. **Ellingrod VL**, Bishop JR (2004). Pharmacogenomics of the Central Nervous System. In:Pharmacogenomics:  Applications to Patient Care. ACCP, Kansas City.
9. Humma LM, **Ellingrod VL**, Kolesar JM (2003). Pharmacogenomics handbook. Lexi-Comp. Hudson, Ohio.
10. **Ellingrod VL** (1999). Disorders affecting psychotropic absorption, metabolism and toxicity. Robinson R and Yates W (eds). In: Psychiatric Treatment of the Medically Ill. Marcel Dekker, New York, 459 – 478.

***Letters to the Editor***

1. Yates, WR, Perry PJ, and **Ellingrod V** (1996). Steroids (letter). Am J Psychiatry; 153: 12.
2. **Ellingrod VL** and Perry PJ (1996). Reassessment of nefazodone. Am J Health System Phar; 53: 2243-2344.

***Podcasts***

1. Newborn outcomes after prenatal exposure to individual antidepressants - Episode 67 by ACCP JOURNALS.

<https://anchor.fm/accp-jrnls/episodes/Newborn-outcomes-after-prenatal-exposure-to-individual-antidepressants---Episode-67-e1b01qn>.

1. Risk of adverse effects with sedative hypnotics and skeletal muscle relaxants - Episode 63. <https://anchor.fm/accp-jrnls/episodes/Risk-of-adverse-effects-with-sedative-hypnotics-and-skeletal-muscle-relaxants---Episode-63-e17av5i>
2. Pharmacotherapy Journals, Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability-Episode 34.

<https://podcasts.apple.com/us/podcast/potential-implications-gut-microbiota-in-drug-pharmacokinetics/id1449625721?i=1000485080292>

1. Current Psychiatry Psychcast, Precision Medicine and Mental Health: Implementing Pharmacogenomics Into your Practice.

<https://www.mdedge.com/podcasts/psychcast/precision-medicine-and-mental-health-implementing-pharmacogenomics-your-practice>

**ABSTRACTS AND POSTER PRESENTATIONS:**

1. Ward KM, Stringer KA, **Ellingrod VL**. Genetic and Metabolite Variability in Folate Metabolism Applied to an Insulin Resistance Model in Patients with Schizophrenia on Atypical Antipsychotics. Presented at the Association for Clinical and Translational Science, Washington DC, March 2019.
2. Perorazio T, Samuels E, Eakin B, Ianni P, **Ellingrod VL**. DIAMOND a Digital Platform for Workforce Development. Presented at the Association for Clinical and Translational Science, Washington DC, March 2019.
3. Ward KM, Stringer KA, **Ellingrod VL.** Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia. Presented at the American College of Neuropsychiatry, Hollywood, FL. December 2018.
4. Ward KM, Stringer KA, **Ellingrod VL.** Variable Free Fatty Acid Composition Associated with SREBF in Schizophrenia Participants Taking Atypical Antipsychotics. Presented at the American Society of Clinical Psychopharmacology, Miami, FL. May 2017.
5. Kolenda A, Grove TB, Burghardt KJ, **Ellingrod VL**. Investigating the Relationship Between Depression, Metabolic Syndrome, and DNA Methylation of the SLC35D3 gene region in Psychotic Disorders. University of Michigan Department of Psychology Research Forum, April 2017
6. Moll A, Kraal AZ**, Ellingrod VL**. Endothelial Nitric Oxide Synthase (eNOS), Metabolic Syndrome, and Cognition in Schizophrenia-Spectrum Disorders. University of Michigan Department of Psychology Research Forum,April 2017
7. Wiese KM, McHugh CE, Yeomans L, Flowers SA, Kraal AZ, Huddle B, Karnovsky A, **Ellingrod VL**, Stringer KA. Serum Metabolomics of Schizophrenia Participants by Fasting Insulin Reveals a Broad Metabolic Risk. Presented at the 3rd Metabolomics Conference, Boston, MA. May 2016.
8. Wiese KM, McHugh CE, Yeomans L, Flowers SA, Kraal AZ, Huddle B, Karnovsky A, **Ellingrod VL**, Stringer KA. Serum 1H-Nuclear Magnetic Resonance (NMR) metabolomics reveals differentiating phenotypes of variable cardiovascular risk in schizophrenia patients receiving atypical antipsychotics” Presented at the Australian Schizophrenia Conference, September 2015.
9. Kraal AZ and **Ellingrod VL**. Gender and antipsychotic differences in metabolic functioning in schizophrenia. Presented at the Australian Schizophrenia Conference, September 2015.
10. Flowers SA and **Ellingrod VL**. Endothelial functioning in schizophrenia patients treated with antidepressants. Presented at the Australian Schizophrenia Conference, September 2015.
11. Burghardt KJ and **Ellingrod VL**. DNA methylation of the RaIA binding protein 1 gene and metabolic syndrome risk in schizophrenia” presented at the American College of Neuropsychopharmacology, Hollywood, FL December 2015
12. Wiese KM, McHugh CE, Yeomans L, Flowers SA, Kraal AZ, Huddle B, Karnovsky A, **Ellingrod VL**, Stringer KA. The pharmacometabolomics of metabolic syndrome in schizophrenia. Presented at the College of Neurologic and Psychiatric Pharmacists meeting April 2015
13. Dougherty R, Kraal AZ, Ellingrod VL. The unique impacts of COMT gene variability by sex on social functioning. Presented at the International Congress on Schizophrenia Research, March 2015.
14. Grove TB, **Ellingrod VL**, Taylor SF. Folate pharmacogenomics, endothelial function, and neurocognition in schizophrenia spectrum disorder. Presented at the Schizophrenia International Research Society Meeting, Florence, Italy, April 2014 – **Finalist for Best Poster Award**
15. Burghardt KJ, Grove TB, **Ellingrod VL**. Global Methylation Levels of Schizophrenia Subjects Supplemented with Folate: A Pilot Stud. Presented at the Schizophrenia International Research Society Meeting, Florence, Italy, April 2014 – **Finalist for Best Poster Award**
16. Burghardt, KJ and **Ellingrod VL**. Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia. Presented at the Pharmacogenomics in Psychiatry Meeting, Hollywood, Florida, June 2013
17. Burghardt, KJ and **Ellingrod VL**. Pharmacometabolomics of Atypical Antipsychotics in Bipolar Disorder: An Untargeted Approach. Presented at the American College of Neuropsychopharmacology Meeting, Hollywood, Florida, December 2013
18. **Ellingrod VL**, Grove TB, Burghardt KJ, Taylor SF. Attenuation of Metabolic Consequences from Atypical Antipsychotic Use in Schizophrenia: Folate Supplementation and the Role of Pharmacogenomics. Presented at the American College of Neuropsychopharmacology Meeting, Hollywood, Florida, December 2013
19. Burghardt KJ, Pop-Busui R, Bly MJ, Grove TB, Taylor SF, **Ellingrod VL**. Brain-Derived Neurotrophic Factor (*BDNF)* 66 Val/Met Polymorphism, Statin Use and Insulin Resistance in the Schizophrenia and Bipolar Populations. Presented at the American College of Neuropsychopharmacology Meeting, Hollywood, Florida, December 2012
20. Burghardt, KJ and **Ellingrod VL**. *BDNF* Met polymorphism, statin use and insulin resistance measures in Bipolar and Schizophrenia population. Presented at the Pharmacogenomics in Psychiatry Meeting, New York, New York, April 2012
21. Ellingrod VL, Grove TB, Taylor SF. Cardiovascular Effects of Folate Supplementation in Schizophrenia: An Interim Analysis. Presented at the American College of Neuropsychopharmacology Meeting, Waikoloa, Hawaii, December 2011
22. Bishop JR**, Ellingrod VL**, Akroush M, Patel S, Rubin LH. Association between LEP -2548 (rs7799039) and obesity during antipsychotic treatment. *Schizophrenia Bulletin* 2011; 37(suppl1): 82.
23. Bishop JR**, Ellingrod VL**, Akroush M, Patel S, Rubin LH. Association between LEP -2548 (rs7799039) and obesity during antipsychotic treatment. Presented at the College of Psychiatric and Neurologic Pharmacists Annual Meeting, May 2011, Phoenix, Arizona (Encore Presentation)
24. Chae SS,Bishop JR**,** Patel S, **Ellingrod VL.** Analysis of glutamate system genes with SSRI-associated sexual dysfunction. Presented at the American Society of Health Systems Pharmacy Annual Meeting, December 2010, Anaheim, California
25. Stringer KA, **Ellingrod VL**, Kong FM, Yuan S, Cai X, Standiford TJ. Angiotensin Converting Enzyme (ACE) Insertion (I)/Deletion (D) Polymorphism and Tissue Plasminogen Activator (tPA) -7351 C/T enhancer Single Nucleotide Polymorphism (SNP) are Associated with Sepsis Induced Actue Lung Injury (ALI). Am J Resp Crit Care Med 2010
26. Houston J, Dharia S, Bishop JR, **Ellingrod VL**, Fijal B, Jacobson JG, Hoffmann VP. Replicated Association of single nucleotide polymorphisms in the *DRD2* and *ANKK1* genes with prolactin increases in olanzapine-treated women. *Biological Psychiatry* 2010; 67(9): 245S.
27. “DNA Methylation Differences in Relation To Metabolic Syndrome and Atypical Antipsychotic Use (AAP) in a Schizophrenia Population Receiving Antipsychotics” Presented at the American College of Neuropsychopharmacology Meeting, December 2009, Ft. Lauderdale, Florida.
28. Bishop JR,Miller DD, **Ellingrod VL**, Holman T. Association between *GRM3* and *GRIN2B* gene variants and symptoms in treatment refractory schizophrenia. *Schizophrenia Bulletin* 2009; 35(suppl 1): 318.
29. Bishop JR**,** Miller DD, **Ellingrod VL**, Holman T. Association between *GRM3* and *GRIN2B* gene variants and symptoms in treatment refractory schizophrenia. Presented at the College of Psychiatric and Neurologic Pharmacists Annual Meeting, April 2009. Jacksonville, Florida (encore presentation)
30. “A pharmacogenetic investigation of Beta-1 Receptor (*ADRB1)* variants and Selective Serotonin Reuptake Inhibitor (SSRI) associated side effects”. Presented at the New Clinical Drug Evaluation Unit (NCDEU) Meeting, June 2009, Ft. Lauderdale, Florida.
31. “Association Between the Brain Derived Neurotrophic Factor (BDNF) Val66Met Variant And Insulin Resistance in Bipolar Subjects Receiving Atypical Antipsychotics”. Presented at the New Clinical Drug Evaluation Unit (NCDEU) Meeting, June 2009, Ft. Lauderdale, Florida.
32. “Relationship Between The Methylenetetrahydrofolate Reductase (MTHFR) 677C/T And Brain Derived Neurotrophic Factor (BNDF) Val66Met Variants And Metabolic Complications Seen With Antipsychotic Use In Schizophrenia Subjects.” Presented at the American College of Neuropsychopharmacology Meeting, December 2008, Scottsdale, Arizona
33. “Serotonin transporter promoter insertion/deletion subtypes (LA/LG), intron 2 VNTR, and Ile425 polymorphisms and SSRI-associated sexual dysfunction”. Presented at the Pharmacogenetics in Psychiatry Annual Meeting, 2007, New York, New York
34. **Ellingrod VL**, Miller DD, Taylor F, Moline J, Holman T, Kerr J. Metabolic Syndrome and Insulin Resistance in Schizophrenia Patients Receiving Antipsychotics Genotyped for the Methylenetetrahydrofolate Reductase (MTHFR) 677CT Polymorphism. College of Psychiatric and Neurologic Pharmacists (CPNP) Annual Meeting, 2007, Colorado Springs, Colorado
35. Bishop JR, **Ellingrod VL**, Moline J, Miller D. The dopamine-2 receptor *Taq*AI polymorphism, prolactin elevation, and bone mineral density in persons with schizophrenia. College of Psychiatric and Neurologic Pharmacists (CPNP) Annual Meeting 2006, Baltimore, Maryland
36. Bishop JR, **Ellingrod VL**, Moline J, Schultz SK, Clayton AH. The serotonin transporter promoter insertion/deletion in patients with depression and selective serotonin reuptake inhibitor (SSRI) associated sexual side-effects. Pharmacogenetics in Psychiatry Annual Meeting 2006, New York, New York
37. **Ellingrod VL**, Bishop JR, Moline, J, Schultz SK, Ekstam-Smith K. 5HT2CR -759C/T Polymorphism of and Glucose Control in the Elderly Receiving Antipsychotics. Pharmacotherapy 2006; 25(10): 1513
38. **Ellingrod VL**, Bishop JR, Moline J, Miller D. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Pharmacotherapy 2006; 25(10): 1479
39. Bishop JR, **Ellingrod VL**, Moline J, Miller D. Association of polymorphisms in the *GRM3* gene response to olanzapine. Pharmacotherapy 2006; 25(10): 1480
40. Miller J, **Ellingrod VL**, Bishop JR. Polymorphisms Of The *GRIN2B* Gene And Olanzapine Response. Presented At The Pharmacy Student Research Conference, Western Region 2005. University of Colorado Health Sciences Center, Denver, Colorado
41. Lin YC, **Ellingrod VL**, Moline J, Miller DD. GRM3 Gene Polymorphisms and Clozapine Response Predictors In Patients With Schizophrenia. Presented At the 6th Annual Clinical and Administrative Division Research Symposium, University of Iowa College of Pharmacy, April 25, 2005. Iowa City, Iowa - ***Finalist for best poster award***
42. Bishop JR**, Ellingrod VL,** Moline J, Miller DD. Association between the polymorphic GRM3 gene and olanzapine response. Presented at the 4th Annual Pharmacogenetics in Psychiatry Meeting, April 15-16, 2005. New York, New York
43. Bishop JR, **Ellingrod VL**, Moline J, Schultz SK. Association between polymorphisms of the G-protein beta subunit (*GNB3*) and serotonin-2A receptor polymorphisms and sexual dysfunction in persons treated with an SSRI for depression. Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, April 10-13th, 2005. San Diego, California - ***Recipient of the Best Poster Award for the Work in Progress Category.***
44. Bishop JR, **Ellingrod VL**, Moline J, Perry PJ (2004). The association of metabotropic glutamate receptor 3 (GRM3) gene polymorphism with clinical response to olanzapine. Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, April 22-25th, 2004. Chicago, Illinois
45. Miller DD and **Ellingrod VL** (2003). Weight Gain Associated with the -759 C/T Polymorphism of the 5HT2C Receptor and Clozapine. Presented at the Pharmacogenetics in Psychiatry Meeting, April 11-12th, 2003. New York, New York
46. Schultz SK. Ponto LB, Magnotta V, Moser DJ, **Ellingrod VL**, Watkins GL, Hichwa RD, O’Leary DS. Assessment of cerebrovascular reserve capacity among person with mild cognitive impairment with [150] water positron emission tomography. Presented at the American College of Neuropsychopharmacology Meeting 2002, Puerto Rico
47. Min DI and **Ellingrod VL**. The effect of CYP3A4\*1B 5’ promoter region polymorphism on cyclosporine pharmacokinetics among healthy volunteers. Pharmacotherapy 2002; 22: 1362
48. Weissman AM, Hartz AJ, Bentler S, Donohue M, **Ellingrod V**, Wisner KL (2001). Meta-analysis of antidepressant levels in lactating mothers, breast milk and nursing infants. Reprinted in Psiquiatria y Salud Integral from the American Psychiatric Association 2001
49. **Ellingrod VL**, Perry PJ, Stille KA, Lund BL, Fleming F, Holman T, Miller DD. 5HT2A Receptor Promoter Polymorphism, -1438G/A And Negative Symptom Response To Olanzapine In Schizophrenia. Pharmacotherapy 2002; 22 (3)
50. Weissman AM, Hartz AJ, Bentler S, Donohue M, **Ellingrod V**, Wisner KL. Meta-analysis of antidepressant levels in lactating mothers, breast milk and nursing infants. Presented at the American Psychiatric Association 2002
51. Schultz SK, **Ellingrod V**, Turvey C, Moser D, Arndt S. A longitudinal study of cognitive status, daily living skills, and psychiatric symptoms in the nursing home setting. Presented at the American College of Neuropsychopharmacology 2001 Annual Meeting, Hawaii
52. **Ellingrod VL**, Min DI, Herman C. Ethnic differences in the distribution of p-glycoprotein among Caucasians and African Americans. Pharmacotherapy 2001; 21: 203
53. Min DI, **Ellingrod VL**, Herman C. The relationship between P-glycoprotein genotypes and cyclosporine pharmacokinetic parameters among healthy volunteers. Pharmacotherapy 2001; 21: 267
54. Schultz SK. **Ellingrod VL,** Ekstam-Smith K, Fleming FW, Filips J, Andreasen NC.Schizophrenia and aging: gender differences in symptom characteristics. Schizophrenia Research 2001; 49 21
55. Perry PJ, **Ellingrod VL**, Lund BC, Bever-Stille K, Miller DD. 5-HT2A and 5-HT2C Receptor Polymorphisms And Predicting Clinical Response to Olanzapine. Schizophrenia Research 2001; 49: 78
56. **Ellingrod VL**, Miller DD, Schultz SK, Wehring H, Arndt S. Polymorphisms of CYP2D6 as a risk factor for weight gain with olanzapine. Schizophrenia Research 2001; 49:283-284.
57. **Ellingrod VL,** Schultz SK, Ekstam-Smith K, Kutscher E, Arndt S, Turvey C.Comparison Of Atypical Antipsychotics In Elderly Dementia Patients With Psychosis. Presented at the American College of Clinical Pharmacy Annual Meeting October 5-8,2000, Los Angeles, California,
58. Schultz SK, **Ellingrod V**, Moser D, Arndt S. Effects of psychiatric symptoms on functional skills in long-term care patients. Presented at the New Clinical Drug Evaluation Unit (NCDEU) 40th Annual Meeting May 30-June 2, 2000, Boca Raton, Florida
59. **Ellingrod VL**, Schultz SK, Arndt S, Perry PJ, Andreasen NC, Holman TL, and Fleming F. Association Between Cytochrome P4502D6 (CYP2D6) Genotype, Neuroleptic Exposure, And Abnormal Involuntary Movement Scale (AIMS) Score. Schizophrenia Research 1999; 36: 90
60. Bever KA, Perry PJ, **Ellingrod VL**, Miller DD, Holman TA, Fleming F. 5HT2A and 5HT2C receptor polymorphism responsible for predicting clinical response to the antipsychotic agent olanzapine. Pharmacotherapy 1998; 18(5): 1175
61. **Ellingrod VL,** Holman TL, Perry PJ, Fleming F, and Andreasen N. Cytochrome P450IID6 (CYP2D6) Genotype in Cigarette Smoking and Non-Cigarette Smoking Patients with Schizophrenia. Pharmacotherapy 1997; 17:1100-1101
62. **Ellingrod, VL,** Perry PJ and Crowe RR. Polymorphism of cytochrome P450IID6 (CYP2D6) in schizophrenics and normal controls. Psychiatric Genetics 1996; 6: 139
63. **Ellingrod VL**, Perry PJ, and Kuperman S. Genetic Markers and Drug Metabolism in Children with Tricyclic Induced EKG Changes. Presented at the American College of Clinical Pharmacy Annual Meeting 1996 , Nashville, Tennessee
64. Yates W, Perry P, MacIndoe J, **Ellingrod V**, Holman T. Can Anabolic Steroids Be Studied in a Randomized and Blinded Design?. Presented at Society of Biological Psychiatry Annual Meeting, May 1995
65. **Ellingrod VL**, Perry PJ, Crowe RR, Chatterjee P, Holman TL, and Fleming FW. Genetic Markers and Drug Metabolism in Patients Receiving Psychotropic Drugs. Presented at the European Conference on Specificity and Variability in Drug Metabolism 1995, Besanon, France
66. Scott SD, Perry PJ, MacIndoe JH, Yates WR, Holman TL, and **Ellingrod VL**. Pharmacodynamic Effects of Supraphysiologic Doses of Testosterone Cypionate (TC) on the Pituitary-Testicular Axis (PTA) of Young Healthy Male Volunteers: Preliminary Report. Presented at the European Conference on Specificity and Variability in Drug Metabolism 1995, Besancon, France

**PLATFORM AND INVITED PRESENTATIONS**

1. “Lessons From An Accidental Academic” Presented at the University of Wisconsin School of Pharmacy, Kremers Lecture, Madison, Wisconsin, April 2024.
2. “Lessons From An Accidental Academic” Presented at the Thomas Jefferson School of Pharmacy, Professionalism Day Keynote speaker, Philadelphia, Pennsylvania, March 2023.
3. “Overview of the PharmD setting in the United States and PharmD program in the University of Michigan” Presented at Peking University, Beijing, China, November 2023.
4. “Pharmacogenomics and Psychiatric Medications” Presented at Fudan University, Shanghai, China, October 2023.
5. “Pharmacogenomics and Psychiatric Medications” Presented at the Annual Texas Psychopharmacology Update, Austin Texas, October 2023.
6. “Advancing the Future of Pharmacy” Presented at China Pharmaceutical University, Nanjing, China, October 2023.
7. “Life Lessons From An Accidental Academic” Presented at Wayne State College of Pharmacy and Health Sciences, Roland T. Lakey Award, Detroit, MI April 2022.
8. “Applying Pharmacogenomics to Clinical Practice” Presented at the College of Psychiatric and Neurologic Pharmacists Annual Meeting, March 2021.
9. “The Role Of Folate Pharmacogenomics On Inflammatory And Metabolic Complications From Atypical Antipsychotic Use In Schizophrenia” Presented at the Precision Medicine World Conference, Menlo Park, CA, February 2020.
10. “Advancing Research at Your Institution by Using Clinical and Translational Science Award (CTSA) Resources” Presented at the American Association of Colleges of Pharmacy, Interim Meeting, San Juan, Puerto Rico, February 2020.
11. “Pharmacogenomics Implementation in Psychiatry”, Presented at the University of Michigan Florida Seminars, West Palm Beach, FL, February 2020.
12. “Pharmacogenomics Implementation in Psychiatry”, Presented at the American Society of Health Systems Pharmacy Annual Meeting, Anaheim, CA, December 2019
13. “Folate’s impact on inflammation and cardiovascular outcomes in Schizophrenia –A placebo controlled trial” Presented at the International Society for Nutritional Psychiatry, London, England, October 2019.
14. “Microbiota Gut Brain Axis a Research Update” Session Chair at Society of Biological Psychiatry, Chicago, IL, May 2019.
15. “ Innovations in Education for Clinical and Translational Research” Presented at the Association for Clinical and Translational Science, Washington DC, March 2019.
16. “Precision Medicines: The Pharmacy Perspective”. Presented at the University of Michigan Health Sciences Luncheon, Ann Arbor, MI, September 2018.
17. “Precision Medicines and Dentistry”. Presented at the University of Michigan College of Dentistry, Ann Arbor, MI, October 2018.
18. “Matters of Life: Dissecting Mechanism of Metabolic Burden in Psychosis, and Moving to Novel Clinical Investigations” Society of Biological Psychiatry, Atlanta, GA, May 2018.
19. “Challenges and Opportunities in Translational Research”. Presented as part of the American Association of Colleges of Pharmacy Catalyst Program. Washington DC, April 2018.
20. “Creating a New Definition of Career Success in Clinical and Translational Research”. Presented at the Association of Clinical and Translational Science Meeting, April 2017.
21. “Microbiome and metabolic disease: the challenges of using microbial therapeutics for disease management. Presented by Dr. Stephanie Flowers, Ellingrod Post Doctorial Fellow at the American College of Clinical Pharmacy Annual Meeting October 2016.
22. “Metabolic Disease Risk: Interaction between Medication and the Microbiome”. Presented by Dr. Stephanie Flowers, Ellingrod Post Doctorial Fellow at the American College of Neuropsychopharmacology, December 2016
23. “Creating a New Definition of Career Success in Clinical and Translational Research”. Presented at the Association of Clinical and Translational Science Meeting, April 2016.
24. “Impact of OPRM1 on metabolic consequences of atypical antipsychotic use. Presented at the Pharmacogenomics in Psychiatry Meeting and Molecular Psychiatry Meeting, September 2016.
25. “Clinical Applications of Pharmacogenomics in Psychiatry” Presented at the University of Texas at Austin, October 2015.
26. “Using the Metabolome to understand the cardiovascular impact of antipsychotics. Society of Biological Psychiatry, April 2015.
27. “Gender and antipsychotic differences in metabolic functioning in schizophrenia” Presented by Ms. Zarina Kraal, Ellingrod PhD Candidate, at the International Congress on Schizophrenia Research, March 2015
28. “Folate’s Role in Schizophrenia” Presented at Wayne State University, March 2015
29. “Folate supplementation and antipsychotic cardiovascular complications” Presented at The Ohio State Department of Psychiatry and Nationwide Children’s Hospital of Ohio, December 2014
30. “Drug Repurposing and Emerging Adjunctive Treatments for Schizophrenia”, Symposium Chair at Schizophrenia International Research Society Meeting, American College of Neuropsychopharmacology, December 2014
31. “Personalized use of SSRIs: how polymorphisms influence therapeutic choices” Presented at the American College of Clinical Pharmacy meeting, October 2014
32. “Folate for Improvements in Cardiovascular Complications in Schizophrenia” Presented at the World Psychiatric Congress, Madrid, Spain, September 2014
33. “Metabolic syndrome in mental illness and the role of folate pharmacogenomics” Presented at Progenity, LLC, Ann Arbor, MI August 2014
34. “My career path to academia and what keeps me here: lessons learned”. Presented at the University of Minnesota College of Pharmacy, Minneapolis, Minnesota, May 2014
35. “Drug Repurposing and Emerging Adjunctive Treatments for Schizophrenia”, Symposium Chair at Schizophrenia International Research Society Meeting, Florence, Italy, April 2014
36. “Pharmacogenomics in Psychiatry- are we on our way to personalized medicine?” Presented at the University of Michigan-Israel Partnership Symposium, Ann Arbor, Michigan, October 2013
37. “The New Era of Personalized Medicine and Companion Diagnostics”. Presented at the Annual Pharmacy Lecture, University of Michigan, Ann Arbor, Michigan, October 2013
38. “Metabolic syndrome in Mental Illness and the role of folate pharmacogenomics” Presented at Purdue College of Pharmacy, Grand Rounds, Indianapolis, Indiana, September 2013
39. “Attenuation of Metabolic Consequences from Atypical Antipsychotic Use in Schizophrenia: Folate Supplementation and the Role of Pharmacogenomics” Presented at the Pharmacogenomics in Psychiatry Meeting, Hollywood, Florida, June 2013
40. “Atypical Antipsychotic use: how do we reduce harm in the college aged mental health population? Presented at the American psychiatric Association Meeting, San Francisco, California, May 2013
41. “Pharmacogenetic and Dietary Predictors of Antipsychotic Associated Metabolic Syndrome and Endothelial Functioning.” Presented at the University of Michigan Department of Psychiatry, Grand Rounds, Ann Arbor, Michigan, January 2013
42. “Pharmacogenetic and Dietary Predictors of Antipsychotic Associated Metabolic Syndrome and Endothelial Functioning” Presented at the University of Tennessee, College of Pharmacy, Memphis, Tennessee, May 2012.
43. “The Influence of Metabolic Syndrome, Physical Activity, and Genotype on Catechol-O-Methyl Transferase Promoter-Region Methylation in Schizophrenia” Presented at the Pharmacogenomics in Psychiatry Meeting, New York, New York, April 2012
44. “Show Me the Money – Grant Writing, Funding Sources and Grant Review Process” presented at the American College of Clinical Pharmacy Annual Meeting October 17, 2011, Pittsburgh, Pennysylvania,
45. “Endothelial Functioning, Pharmacogenetics Factors and Omega 3 Fatty Acids in Schizophrenia Subjects Receiving Antipsychotics” Presented at the Adipogenic and Metabolic Effects of Antipsychotic Drugs Conference, July 11-12, 2011, Newark, NY
46. “Methylenetetrahydrofolate Reductase (MTHFR) 677C/T And Catechol-O-Methyltransferase (COMT) Val158Met Variants And Endothelial Functioning In Schizophrenia Subjects Treated With Antipsychotics”. Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, Phoenix, Arizona, May 2011.
47. “Endothelial Functioning and Omega 3 Fatty Acids in Schizophrenia Subjects Receiving Antipsychotics” Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, Phoenix, Arizona, May 2011.
48. “Endothelial Functioning and Omega 3 (n3) Fatty Acids in Schizophrenia Subjects Receiving Antipsychotics “Presented at the International Congress on Schizophrenia Research (ICOSR) Meeting, Colorado Spring, April 2011, Colorado
49. “Effects of Folate Supplementation in Atypical Antipsychotic Linked Metabolic Outcomes: An Interim Analysis” Presented at the International Congress on Schizophrenia Research (ICOSR) Meeting, April 2011, Colorado Spring, Colorado
50. “How to initiate your Research program Writing Specific Aims, Mentoring, K-Awards, And The Grant Review Process” presented at Touro University, February 2011, California,
51. “Faculty Orientation and Development Workshop” presented at at Midwestern University College of Pharmacy, January 2011, Pomona, California,
52. “Show Me the Money – Grant Writing, Funding Sources and Grant Review Process” Presented at the American College of Clinical Pharmacy Annual Meeting October 2010, Austin, Texas
53. PharmGenEd™ Psychiatry I Module: Depression. <http://www.scivee.tv/node/25243>. Released on October 22, 2010 (275 views)
54. “Continued Professional Development” Presented at the Michigan Society of Health Systems Pharmacy Residency Meeting, June 2010, Lansing, Michigan
55. “Mediating Relationships Between Atypical Antipsychotic Associated Metabolic Syndrome, Inflammation, and Folic Acid Metabolism” Presented at the American College of Neuropsychopharmacology Meeting, Miami Beach, Florida, December 2010,
56. “A Pilot Examination of Endothelial Function in Schizophrenia” Presented at the Michigan Institute for Clinical Research Annual Research Symposium, Ann Arbor, Michigan, October 1, 2010.
57. “Methylenetetrahydrofolate Reductase (MTHFR) 677C/T And Catechol-O-Methyltransferase (COMT) Val158Met Variants And Endothelial Functioning In Schizophrenia Subjects Treated With Antipsychotics” Presented at the Pharmacogenetics in Psychiatry Meeting, April 2010 New York, New York
58. “Pharmacogenomics at Michigan” Presented at the University of Michigan Depression Center Colloquium. February 2010, Ann Arbor, Michigan
59. “Funding for PharmD PhD programs” Presented at the Pharmacy Clinical Sciences, PhD Summit. November 2009, Los Angeles, California
60. “Pharmacogenetics of Folic Acid Metabolism and Metabolic Disturbances in Schizophrenia ” Presented at the World Congress of Psychiatric Genetics Meeting, November 2010, San Diego, California
61. Pharmacogenomics and integration into clinical practice” Presented at the Midwest Psychopharmacology Update, October 2009, Cincinnati, Ohio
62. “New Innovations and Clinical Applications of Genomics” Plenary Speaker at the American College of Clinical Pharmacy Spring Forum, April 2009, Orlando, Florida.
63. Pharmacogenomics Primer and Update” Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, April 2009, Florida
64. “Pharmacogenetics of Folic Acid Metabolism and Metabolic Disturbances in Schizophrenia” Presented at the International Congress of Schizophrenia Research Meeting, March 23, 2009, San Diego, California
65. “Using Pharmacogenetics to Dissect Antipsychotic Metabolic Complications” Presented at the University of Iowa Research Rounds, February 2, 2009, Iowa City, Iowa
66. “Pharmacogenetics of Antipsychotic Associated Metabolic Complications in Schizophrenia” Presented at the American Association of Pharmaceutical Sciences Meeting, November 11, 2008, Atlanta, Georgia.
67. “Pharmacogenomics and the role of biomarkers in schizophrenia treatment” Presented at the 1st Annual Meeting of the Schizophrenia International Research Society, June 2008, Venice, Italy
68. “Using Pharmacogenomics in the Clinic” Presented as part of the University of Michigan Depression Center Colloquium Series. December 2007, Ann Arbor, Michigan.
69. “Using Pharmacogenomics in our Quest for Individualized Medicine: where do we stand and where we are going?” Presented at the South Dakota State University 17th annual Pharmacy Research Presentations and Convocation, October 22, 2007, Brookings, South Dakota
70. “Metabolic Syndrome and Insulin Resistance in Schizophrenia Patients Receiving Antipsychotics Genotyped for the Methylenetetrahydrofolate Reductase (MTHFR) 677CT Polymorphism” Presented at the Pharmacogenomics in Psychiatry Meeting, April 13, 2007, New York, New York

### “Application of Pharmacogenomics to Clinical Practice in Psychiatric Patients” Presented at the 18th Annual Psychiatric Pharmacotherapy Update, The University of Texas at Austin, October 21, 2006, Austin, Texas

1. “Pharmacogenomics in Psychiatry” Presented at the American College of Clinical Pharmacy, Ohio Chapter Annual Meeting, October 11, 2006, Cleveland, Ohio
2. “Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia” Presented at the 5th Annual Pharmacogenetics in Psychiatry Meeting, April 8, 2006, New York, New York.
3. “One Size Does Not Fit All – The Promise of Pharmacogenetics” Presented at the Iowa Pharmacy Association Educational Expo, January 28, 2006, DesMoines, Iowa
4. “Pharmacogenomics” Presented at the Current Topics in Allergy and Clinical Immunology Conference for the University of Iowa Carver College of Medicine, October 28, 2005, Iowa City, Iowa
5. “Pharmacogenomics of Schizophrenia Treatment” Presented as part of the Rennebohm Symposium at the University of Wisconsin, College of Pharmacy, September 20-22, 2005, Madison, Wisconsin
6. “The Pharmacogenetics of Schizophrenia Treatment” Presented at the University of Michigan College of Pharmacy Research Seminar, April 22, 2005, Ann Arbor, Michigan
7. “Clinical Applications of Genetics in the Treatment of Schizophrenia.” Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, April 11, 2005. San Diego, California
8. “Breakout session: Meet the experts: How to write a research grant” Presented at the College of Psychiatric and Neurologic Pharmacists Meeting, April 12, 2005. San Diego, California
9. “Significant Paper in Psychiatry” Presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting, October 25, 2004. Dallas, Texas
10. “Pharmacogenomics in Psychiatry” Presented as Grand Rounds, Evanston Northwestern Health Care Department of Psychiatry, June 15, 2004, Evanston, Illinois
11. “Pharmacogenetics and Schizophrenia” Presented as the Young Investigator Lectures at the ACCP Spring Meeting, April 27, 2003Palm Springs, California
12. “Psychopharmacology Part 1” Presented at the Geriatric Psychiatry Seminar, Department of Psychiatry, College of Medicine, February 25, 2003, Iowa City, Iowa
13. “Pharmacogenomics in Psychiatry: a review and update” Presented at the 8th Annual Midwest Neuro Psychiatric Pharmacy Conference, November 1, 2002, Cleveland, Ohio
14. “Treatment of Dementia” Presented at the Training to Enhance Service Delivery to Older Adults with Mental Illness, University of Iowa College of Medicine, Department of Psychiatry and College of Nursing, August 25, 2002, Iowa City, Iowa
15. “The Pharmacists’ Role in Monitoring Antipsychotic Therapy” Presented at the Iowa Pharmacy Association Meeting, June 21, 2002, Des Moines, Iowa
16. “New Findings and Therapies in Psychiatric Pharmacy” Presented at the ACCP Psychiatry Preparatory Course, April 9, 2002, Savannah, Georgia
17. “New Practices in Psychiatric Pharmacy” Presented at the ACCP Psychiatry Preparatory Course, April 9, 2002, Savannah, Georgia
18. “Substance Abuse and Pain Disorders: A Case Based Lecture” Presented at the ACCP Psychiatry Preparatory Course, April 21, 2001, Salt Lake City, Utah
19. “Eating and Personality Disorders: A Case Based Lecture” Presented at the ACCP Psychiatry Preparatory Course, April 21, 2001, Salt Lake City, Utah,
20. “Dementia, Delirium, and Agitation: A Case Based Lecture” Presented at the ACCP Psychiatry Preparatory Course, , April 20, 2001, Salt Lake City, Utah
21. “Sexual Side Effects of Antidepressants” Presented at the University of Iowa College of Medicine’s Women’s Mental Health Through the Life Cycle: Mood, Food, and Sex, March 30, 2001Iowa City, Iowa
22. “Differentiating Dementias for Appropriate Treatment” Presented at the American Pharmaceutical Association 148th Annual Meeting and Exposition, March 17, 2001, San Francisco, California
23. “Pharmacotherapy in the Elderly. Are we really doing our best?” Presented at the Evanston Health Care Conference, October 7, 2000, Evanston, Illinois
24. “Eating and Personality Disorders: A Case Based Lecture” Presented at the ACCP Psychiatry Preparatory Course, June 10,2000, St. Louis, Missouri
25. “Dementia, Delirium, and Agitation: A Case Based Lecture” Presented at the ACCP Psychiatry Preparatory Course, June 10,2000, St. Louis, Missouri
26. “New Treatments for Brain Disorders” Presented to Linn County Alliance for the Mentally Ill, May, 2000, Cedar Rapids, Iowa
27. “Herbal use in the Elderly”, Presented at the Center on Aging, Graduate Seminar series, University of Iowa, Center on Aging, May 10, 2000, Iowa City, Iowa
28. “Psychotropic Drug Interactions” Presented to Nurses and Nursing students on Medical Psychiatry Unit, November 1999, University of Iowa Hospitals and Clinics, Iowa City, Iowa
29. **“**Association Between Cytochrome P4502D6 (CYP2D6) Genotype, Neuroleptic Exposure, And Abnormal Involuntary Movement Scale (AIMS) Score”. Encore Poster Presentation at American College of Clinical Pharmacy Annual Meeting, October 1999, Kansas City, Missouri
30. “Psychopharmacology Update 1999” Presented at the Iowa Pharmacy Association Meeting, June 11, 1999, Iowa City, Iowa
31. “Treatment of Depression in Primary Care” Presented at the College of Pharmacy Continuing Education Fall Seminar. University of Iowa, College of Pharmacy, October 9, 1998, Iowa City, Iowa
32. “Neuroleptic Malignant Syndrome: A Variant of Drug Induced Lethal Catatonia” Presented at the Department of Psychiatry Grand Rounds. University of Iowa, College of Medicine, Department of Psychiatry, September 22, 1998, Iowa City, Iowa
33. “Depression and Therapy” Presented at the Internal Medicine Core Conference for Internal Medicine Resident Physicians, University of Iowa, College of Medicine, December 29, 1997, Iowa City, Iowa
34. **“**Polymorphism of cytochrome P450IID6 (CYP2D6) in Schizophrenics and Normal Controls”. Encore Poster Presentation at American College of Clinical Pharmacy Annual Meeting, November 1999, Phoenix, Arizona.
35. “Psychotropic Agents” Presented at the College of Nursing’s Pharmacology Update for Advanced Practice Nurses, September 30, 1997, Iowa City, Iowa
36. “Genetic Polymorphism in the Serotonin 5HT2A and 5HT2C Receptors and Prediction of Response to Clozapine” presented at the University of Iowa College of Pharmacy Clinical Pharmacy Seminar (46: 280), March 12, 1997. Iowa City, Iowa
37. “Overview of Drug Metabolism in the Elderly”, Presented at the 13th Annual Mental Health Nursing Conference, October 9-10, 1996, Iowa City, Iowa
38. “Psychopharmacology Drugs and the Elderly”, Presented at the 13th Annual Mental Health Nursing Conference, October 9-10, 1996, Iowa City, Iowa
39. “Pharmacotherapy of Obsessive Compulsive Disorder” Presented at the Psychiatry Postgraduate Conference of the Iowa Psychiatric Society, September 20-21, 1996, Cedar Rapids, Iowa
40. “Genetic Markers and Drug Metabolism in Children with Tricyclic Induced EKG Changes”, Presented to Clinical Pharmacy Faculty, and Pharm.D. Candidates, University of Iowa, College of Pharmacy, October 30, 1995, Iowa City, Iowa
41. “Update on Serotonin Reuptake Inhibitors and Drug Interactions”, presented to Psychiatrists and Pharmacists in the Waterloo, Iowa area, October 18, 1995, Waterloo, Iowa
42. “Psychopharmacology Update”, presented at the 12th Annual Mental Health Nursing Conference, October 10-11, 1995, Iowa City, Iowa
43. “Genetic Markers of Drug Metabolism in Patients Taking Psychotropic Medications”, Presented at the Midwest Regional Residency Conference, April 29, 1995, Stillwater, Minnesota
44. "Psychoendocrinology of Anabolic Steroid Abuse: Research Update", Presented to Clinical Pharmacy Faculty, and Pharm.D. Candidates, University of Iowa, College of Pharmacy, October 1994, Iowa City, Iowa
45. "Pathogenesis and Treatment of Bacterial Meningitis", presented to Clinical Pharmacy Faculty, Staff and Pharm.D. Candidates, University of Minnesota Hospital and Clinics, March 1994, Minneapolis, Minnesota
46. "Carnitine for the Use of Deficiency, and Prevention of Valproate Hepatotoxicity", presented to Clinical Pharmacy Faculty, Staff, and Pharm.D. Candidates, United Hospital, November 1993, St. Paul, Minnesota
47. "Augmentation of Treatment Resistant Depression", presented to Clinical Pharmacy Faculty, Staff and Pharm.D. Candidates, University of Minnesota, College of Pharmacy, November 1993, Minneapolis, Minnesota

**DIDACTIC TEACHING**

***PharmD, Bachelors of Science, and Clinical Pharmacy Translational Sciences Curriculums (University of Michigan College of Pharmacy)***

*Fall Semester*

2016-2019 Pharmacy 702-Pharmacology and Therapeutics III

Role: Lecturer (4.5 contact hours)

2010-2012 Pharmacy 451-Pharmaceutical Care III

 Role: Case Evaluator (4 contact hours)

2009-2016 Pharmacy 431-Pharmacology and Therapeutics II

Role: Lecturer (4.5 contact hours)

2007-2009 Pharmacy 680-PharmD Seminar

Role: Coordinator (24 contact hours)

2006-2019 Pharmacy 680-Pharm D Seminar

Role: Preceptor (2 students/year)

*Winter Semester*

2019-present Pharmacy 727-Career Development for PhD Students and Post-Doctoral Fellows

 Role: Co-Coordinator (15 contact hours)

2019-present Pharmacy 216-Introduction to Precision Health

Role: Coordinator (15 contact hours)

2018-present Pharmacy 647-Introduction to Clinical Trials

Role: Coordinator (30 contact hours)

2011-2016 Pharmacy 432-Pharmacology and Therapeutics II

Role: Coordinator (60 contact hours)

2010-2016 Pharmaceutics 465-Pharmacogenomics

 Role: Presentation Evaluator (2-4 contact hours)

2010 Pharmacy 402-Introduction to the Profession

 Role: Group Facilitator (3 contact hours)

2010-2020 Pharmacy 452-Pharmaceutical Care IV

Role: Lecturer (20 contact hours)

2009-2020 Pharmacy 432-Pharmacology and Therapeutics II

Role: Lecturer (12 contact hours)

2007-2009 Pharmacy 680-PharmD Seminar

Role: Coordinator (30 contact hours)

2006-present Pharmacy 680-Pharm D Seminar

Role: Preceptor (2 students/year)

***On Job On Campus (OJOC) Program Curriculum (University of Michigan School of Public Health)***

2009-2015 Biostatistics 558/Pharmacy 602 Clinical Trials and Drug Design

Role: Coordinator and Lecturer (54 contact hours)

2011-2015 Biostatistics 559 Grant Writing

 Role: Coordinator and Lecturer (54 contact hours)

***Miscellaneous Lectures (University of Michigan School of Medicine, Genetics, and Dentistry)***

*Fall Semester*

2008-2015 Sedative and Hypnotic Pharmacology and Therapeutics Review

Presented to the Sleep Medicine Senior Fellows (2 contact hours)

*Winter Semester*

2009-present Dental 602 The Neural Basis of Orofacial Pain and Function

Intro to Pharmacogenetics (2 contact hours)

2008-present Pharmacogenetics in Psychiatry

Presented to the PGY4 Neuropsychiatry Resident (3 contact hours)

2008-2014 Pharmacogenetics for Genetic Counseling

Presented to the first year genetic counseling student class (2 contact hours)

***PharmD Curriculum (University of Iowa College of Pharmacy)***

1995-2006 Clinical Psychopharmacology Seminar for to resident physicians in psychiatry, neuropsychology fellows, and advanced practice psychiatry nurses.

Course Coordinator

1998–2000 Pharmacotherapy: Psychiatric and Neurologic Disorders (46:153)-3 semester hours

2003–2005 Pharmacotherapy: Psychiatric and Neurologic Disorders (46:164)-2 semester hours

2005–2006 Introduction to Clinical Pharmacogenetics (46:169) – 2 semester hours

2005–2006 Advanced Psychopharmacology (46:204) – 2 semester hours

2005–2006 Advanced Psychopharmacology (46:203) – 2 semester hours

2006–2006 Pharmacogenetics (46:269) – 3 semester hours

2006–2006 Clinical Pharmaceutical Sciences Seminar (46:280) – 2 semester hours

Lecturer

2005-2006 Introduction to Clinical Pharmacogenetics (46:169)

2002–2006 Advanced Psychopharmacology (46:203 and 46:204)

2000–2006 Pharmacotherapy of Psychiatric and Neurologic Disorders (46:164)

2003–2006 Clinical Pharmacokinetics

1998–2004 Pharmacotherapy: Psychiatric and Neurologic Disorders (46:153)

Previous Teaching August 1996-May 1998

Drug Induced Diseases (46:173): Drug Induced Liver Disease

Drug Induced Diseases (46:173): Neuroleptic Malignant Syndrome

Drug Induced Diseases (46:173): Drug Induced Seizures

Pharmacotherapy III (46:165): Pharmacotherapy of Insomnia

Pharmacotherapy III (46:165): Pharmacotherapy of Eating Disorders

Group Discussion Leader:

January 2000-April 2000 Clinical Professional Skills (46:195)

January 1999-April 1999 Clinical Professional Skills (46:195)

January 1998-April 1999 Clinical Professional Skills (46:195)

November 1999: Introduction to Pharmaceutical Care (46:049): Problem Based Learning

November 1998: Introduction to Pharmaceutical Care (46:049): Problem Based Learning

December 1996: Introduction to Pharmaceutical Care (46:049): Constipation

October 1996: Introduction to Pharmaceutical Care (46:049): Allergic Rhinitis

October 1995: Introduction to Pharmaceutical Care (46:049): Asthma

***University of Iowa-College of Medicine, Department of Psychiatry***

1995-1996 Clinical Psychiatry (73:5). Lecture on Pharmacotherapy and Pharmacology of Antimanic medications given to third year medical students as part of their psychiatry rotation

***Pharm D Student Service (University of Michigan)***

2009-2012 Faculty Advisor for Academy of Students of Pharmacy Antibiotic Resistance/Hand Washing Committee

2008-2010 Faculty Advisor for Academy of Students of Pharmacy Smoking Education Committee

**EXPERIENTIAL TEACHING**

***Pharm D Curriculum (University of Michigan College of Pharmacy)***

Pharm D Investigation Students (Pharmacy 565 and Pharmacy 570 (3 credits annually)

**2020-2023**

Sara Baghdadi

**2019-2021**

Alyssa George, Angelina Jeong, Briana Kowal

**2017-2019**

Pooja Kumar

**2016-2018**

Jessica Gerdes

**2015- 2017**

Chelsea Liebowitz, Lisa Chen

**2014- 2016**

David Dadinmov, Jenny Lin

**2013- 2015**

Charles Yoo, Sonja Grinfeld

**2012- 2014**

Lydia Beneitz, Erin Dukarski, Sahar Seydin, Josh Johnson

**2011-2013**

Kristen Gardner, Thomas Vassas, Arnold Andreason,

**2010-present**

Corey Edge, Nancy Janiczek-Dolphin, Stephen Lott, Anna Polk

**2009-2011**

Giovanni Lares, Jessica Lynn Moreno, Mirae Shin

**2008-2010**

Tiffany Scott Horton

**2007-2009**

Amber Bradley, Heidi Cole, Carrie Deierlein, Jillian Descourouez, Dustin Gladden, David Johnson, Elizabeth McCarty, Megan Meden, Jennifer Ng, Mira Patel Elizabeth Renner, Janet Sachenko, Jerome Stevens, Zhenyi Zhang

Advanced Pharmacy Practice Experiences

2013-present Pharmacy 795 Kenya Advanced Pharmacy Practice Experience (6 students per year)

2007-2021 Pharmacy 690 Elective Clerkship Preceptor (2-6 students per year)

***PharmD Curriculum (University of Iowa College of Pharmacy)***

Research and Clinical Clerkship

2001 – 2006 Pharmacogenetics Research Clerkship (46:184) 4 semester hours

1997 –2001 Psychiatry Pharm.D. Clerkship (46:184) 4 semester hours

1997-2006 Advanced Psychiatry Pharm.D. Clerkship (46:184) 4 semester hours

1996-1999 Psychiatry B.S. Clerkship (46: 184) 4 semester hours

1997 Pharmacy project elective (46:101) 3 semester hours

***Summer Multidisciplinary Clinical Researchers in Training Program (MCRiT) Students (Michigan Institute for Clinical Research (MICHR))***

June-August 2007 Duong Nguyen

June-August 2008 Megan Meden

June-August 2008 Jim Stevenson

June-August 2009 Stephen Lott

June-August 2010 Kristen N. Gardner

June-August 2011 Arnold Andreasen

June-August 2011 John Zaccardelli and Charles Yoo

June-August 2017 Steven Gabriel

***Summer Multidisciplinary Clinical Researchers in Training Program (MCRiT) Global Students (Michigan Institute for Clinical Research (MICHR))***

June-August 2013 Alena Wu

June-August 2014 Emily Van Wieren, Craig Michael, Charlotte Buckley

June-August 2015 Blaise Nudeke, Brian Pauls, Blake Jackson

June-August 2016 Erika Kim

## **POST-GRADUATE EDUCATION**

## ***Residency Research Lecture Series (University of Michigan)***

2009-2013 Outcome Variables, Reliability/Validity/Confounding

2009-2013 Data Collection Instruments

## ***Residency Preceptor (University of Iowa)***

1998-1999 Brian Lund, Pharm.D.

Pharmacy Psychiatry Residency Program

 University of Iowa, College of Pharmacy

***Psychopharmacology Fellowship Preceptor (University of Michigan)***

2017-2019 Beatriz Mitrzyk, Pharm.D,

Psychopharmacology and Pharmacogenetics Fellowship University of Michigan, College of Pharmacy

2014-2017 Kristen Weise, Pharm.D,

Psychopharmacology and Pharmacogenetics Fellowship University of Michigan, College of Pharmacy

2014-2017 Stephanie Flowers, Pharm.D, Ph.D.

Psychopharmacology and Pharmacogenetics Fellowship University of Michigan, College of Pharmacy

2011-2014 Kyle Burghardt, Pharm.D.

Psychopharmacology and Pharmacogenetics Fellowship University of Michigan, College of Pharmacy

***Psychopharmacology Fellowship Preceptor (University of Iowa)***

2002–2005 Jeffrey R. Bishop, Pharm.D. M.S.

Psychopharmacology and Pharmacogenetics Fellowship University of Iowa, College of Pharmacy

2001-2004 Tami Argo, Pharm.D., M.S.

Psychopharmacology Fellowship

 University of Iowa, College of Pharmacy

2000-2002 Ryan Carnahan, Pharm.D.,M.S.

Psychopharmacology Fellowship

 University of Iowa, College of Pharmacy

1999-2001 Brian Lund, Pharm.D., M.S.

Psychopharmacology Fellowship

 University of Iowa, College of Pharmacy

1996-1999 Kristy Bever Stille, Pharm.D.

Psychopharmacology Fellowship

 University of Iowa, College of Pharmacy

***Graduate Students Advisor (University of Michigan)***

2020-2023 Ozioma Edokobi, PharmD/PhD Candidate in Clinical Pharmacy Translational Sciences, University of Michigan Rackham Graduate College

2016-2021 A.Zarina Kraal, MS, PhD Candidate in Psychology, University of Michigan Rackham Graduate College

2014-2016 Jamie Carnahan, PhD Candidate in Pharmaceutical Sciences, University of Michigan Rackham Graduate College (committee member)

2012-2016 Tyler B. Grove, BS, PhD Candidate in Psychology, University of Michigan Rackham Graduate College

2008–2009 Kelan Thomas, Pharm.D., Master Candidate in Clinical Research, Multidisciplinary Clinical Researchers in Training Program (MCRiT), University of Michigan College of Pharmacy and Michigan Institute for Clinical and Health Research

2006-2009 Jessica Moline, B.S., Master Candidate in Genetic Counseling University of Michigan, Human Genetics, Genetic Counseling Program

***Masters Students Advisor (University of Iowa)***

2005–2006 Jesse Hollanbaugh, Pharm.D., Ph.D. Candidate in Clinical Pharmaceutical Sciences, University of Iowa College of Pharmacy, Clinical and Administrate Division

2004–2006 Mohammad Shawaqfeh, Masters Candidate in Clinical Pharmaceutical Sciences, University of Iowa College of Pharmacy, Clinical and Administrate Division

2003–2005 Ying-Chi (Alice) Lin, Masters Candidate in Clinical Pharmaceutical Sciences, University of Iowa College of Pharmacy, Clinical and Administrate Division

***Masters Thesis Defense Committees (University of Iowa)***

April 2004: Yen-Ying Lee

April 2005: Ying-Chi (Alice) Lin

April 2005: Charlie Lin

April 2005: Wendy Leu

April 2006: Mohammad Shawaqfeh

***PhD Defense Committees (University of Toronto, Canada)***

December 2014 Nabiliah Choudhry

**MENTORING**

***Mentor for Workshops and Mentoring Programs***

2020-present Addressing Equity and Inclusion in Mentoring - Mentor Training (held two to three times yearly)

2017 -present MICHR Mentoring Academy (held one to two times yearly)

2015 National Research Mentor Network (NRMN) Certification and Training

2011 Michigan Institute for Clinical Research (MICHR) Panel Discussant for “Establishing Value in Research Mentoring: Recognition and Education Workshop” July 21, 2011

2010–2021 Mentor for American College of Clinical Pharmacy Focused Investigator Training (FIT) and Mentored Investigator Research Training (MeRIT) Programs

2021 mentees

 David Dadimov, PharmD, University of California San Francisco

Lee Hu Nguyen, PharmD, University of California Irvine

Titiola Mitsuko Afolabi, PharmD, Midwestern University

Paul Jisuen Won, University of Southern California

2019 mentee

 Mikel Jones, PharmD – University of Kentucky

2017-mentee

 Ryan Funk, PharmD, PhD- University of Missouri

 Jennie Jarrett, PharmD, Ed- University of Illinois Chicago

2016 mentees

 Jason Karnes, PharmD, PhD – University of Arizona

Ginah Nightingale, PharmD – University of Philadelphia

Charlene Williams, PharmD– University of North Carolina

2015 mentees

 Christine Eisenhower, PharmD– University of Rhode Island

2014 mentees

 Raymond Cha, Pharm.D, - Wayne State University

 Allison Blackmer, PharmD – University of Michigan

 Emi Minejima, PharmD – University of Southern California

2013 mentees

 Hassan Almoazen, Ph.D., University of Tennessee

Jeffrey Gonzales, Pharm.D.,BCPS, FCCM – University of Maryland

Kalen Manasco, PharmD - Georgia Regents University

Catherine O'Brien, PharmD - University of Arkansas

 2011 mentees

 Neha Sheth, Pharm.D., University of Maryland

 Rustin Crutchley, Pharm.D., University of Houston

 2010 mentees

Roy Parish, B.S. Pharm.D., University of Louisiana

Pam Pawloski, B.S, Pharm.D., Health Partners Research Foundation

1998-2006 Mentor in the Mentoring program sponsored by Iowa Pharmacy Association

***Career Development Award (K award) mentoring/collaboration***

Paul Burghardt, Ph.D. Assistant Professor, University of Michigan, School of Medicine, Department of Psychiatry

Simon Evans, Ph.D. Assistant Professor, University of Michigan, School of Medicine, Department of Psychiatry

Michael Dorsch, Pharm.D. Clinical Assistant Professor, University of Michigan, College of Pharmacy, K23 Mentor

Cathy Van Poznek M.D. Assistant Professor, University of Michigan, School of Medicine, Department of Oncology, K23 mentor

Jess Fiedorowitz, M.D. Assistant Professor, University of Iowa, Carver College of Medicine, Department of Psychiatry, K23 Mentor

Chadi Calarge, M.D. Assistant Professor, University of Iowa, Carver College of Medicine, Department of Psychiatry, K23 Mentor

Kelly Lee, Pharm.D. Assistant Professor, University of California San Diego, College of Pharmacy, K23 Mentor

Fu Luan, M.D. Assistant Professor, University of Michigan, School of Medicine, Department of Nephrology, K23 Mentor and mentor on other grants

Shannon Saldana, Pharm.D., Assistant Professor, University of Cincinnati Children's Hospital,

K23 Mentor

Leigh Beglinger, Ph.D. Associate Professor, University of Iowa, Carver College of Medicine, Department of Psychiatry, K23 Consultant

David Moser, Ph.D., Associate Professor, University of Iowa, Carver College of Medicine, Department of Psychiatry, K23 Consultant

***Additional Mentees (University of Michigan College of Pharmacy)***

Michael Dorsch, Pharm.D., Assistant Professor

Jamie Park, Pharm.D. Clinical Professor

Rima Mohammad, PharmD, Clinical Assistant Professor

Daniel Hertz, PharmD, PhD, Assistant Professor

Toni Coe, PharmD, PhD, Assistant Research Professor

Jasmine Luzum, PharmD, PhD, Assistant Professor

Corey Lester, PharmD, PhD, Assistant Research Professor

***Additional Mentees (Touro University College of Pharmacy)***

Tristan Lindfelt, Pharm.D. BCPS, Assistant Professor of Clinical Sciences & Residency Director

**PROFESSIONAL AFFILIATIONS:**

2021-present American Society for Clinical Pharmacology and Therapeutics (ASCPT)

2020-present Pharmacogenomics Research Network, Founding member

2019-present University of Michigan Precision Health

2014-present Society of Biological Psychiatry, Member

2012-present American College of Neuropsychopharmacology (ACNP) Full Member

2007-present Schizophrenia International Research Society (SIRS)

2006-present University of Michigan Depression Center

2005–present Schizophrenia Research Forum

1999-2006 American Association of Geriatric Psychiatry (AAGP)

1998-present National Alliance for the Mentally Ill (NAMI)

1998-present College of Psychiatric and Neurologic Pharmacists (CPNP) Founding Member

1997-present American Association of Colleges of Pharmacy (AACP)

1996-present The International Society for the Study of Xenobiotics (ISSX)

1996-present International Society of Psychiatric Genetics (ISPG)

1994-present American College of Clinical Pharmacy (ACCP)

 1998–present Full Member

 1994–1998 Associate Member

1998-2006 Iowa Pharmacy Association (IPA)

1994-1998 Iowa Pharmaceutical Association (IPA)

1994-2004 Johnson County Pharmacists' Association (JCPA

1992-1994 American Pharmaceutical Association (APhA)

1992-2004 American Society of Health-Systems Pharmacists (ASHP) Psychopharmacy/Neurology Network member

1992-1993 Minnesota Pharmaceutical Association (MPhA)

1989-1992 Academy of Student of Pharmacy (ASP)

1992-2006 Kappa Psi Pharmaceutical Fraternity, Graduate Chapter.

1989-1992 Kappa Psi Pharmaceutical Fraternity, Collegiate Chapter.

**COMMITTEE AND ADVISER APPOINTMENTS**

University of Michigan, College of Pharmacy

2019-2022 Chair, Graduate Education Committee

2019 Chair, Clinical Social and Administrative Sciences Department Promotion Review Committee

2014 Chair, Clinical Social and Administrative Sciences Department Promotion Review Committee

2013-2014 Chair, Dean Search Committee

2013-2016 International Committee

2011 Faculty Search Committee, Clinical Educator Position

2010-2022 Research Resources Committee

2010-2013 Accreditation Steering Committee

2010-2013 College of Pharmacy Executive Council

2010-2019 Self Care and Therapeutic Curriculum Sub Committee

2009-2012 Faculty Development and Assessment Committee

 2010-present Co-Chair

2009-2017 Pharmacogenetics Curricular Sub-committee

2008-2013 Clinical Social and Administrative Sciences Research Seminar Chair

2008 Faculty Search committee, Psychopharmacology Clinical Pharmacist

2007-2010 Pharm.D. Investigations Committee

2007-2010 Valteich Review Committee

2007 Faculty Search committee, Psychopharmacology Clinical Pharmacist

University of Iowa, College of Pharmacy

2004–2005 Committee for Review of Dean

2004–2005 Clinical and Administrative Division Faculty Search Committee

2003–2004 Clinical Scientists PhD Task Force

2002–2006 Space and Laboratory Utilization Committee

2002–2003 Pharmaceutical Sciences Division Head Search Committee

200 2002 CAP Faculty retreat planning committee

2000 – 2006 University of Iowa Student Pharmacy Recovery Network Committee

1999-2000 Clinical and Administrative Division Academic Affairs Committee

1999-2000 Committee for the Development of a Bachelors of Science in Pharmaceutical Chemistry

1997-2006 Faculty Adviser, Kappa Psi Pharmaceutical Fraternity, In

1998- 2000 Curriculum Committee Subcommittee For The Coordination of Therapeutics, Medical Chemistry, And Pharmacology

1998-2000 Ambulatory Pharmaceutical Care Quality Improvement Team, University of Iowa Hospital and Clinics Department of Pharmaceutical Care

1998-1999 Women’s Health Initiative Planning Committee

1998-1998 Committee for Review of Dean

University of Michigan

2024-2026 Chair, Health Science Deans Council

2021-2023 Member, Student Mental Health Committee- Graduate/Professional Student Needs Work Team

2021-present Member, University of Michigan Joint Institute Grant Review Committee

2021-2022 Member, Provost’s Committee for Visitor Policies

2021-2022 Member, UMOR’s Committee for Data Analysis Needs Assessment

2020-2024 Member, Laboratory Research Safety Committee

2019-2020 Member, Michigan Institute for Clinical and Health (MICHR) Director Search

2019-2020 Member, Depression Center Chair Search Committee

2018-2021 Member, Depression Center LINC Committee

2016-2018 Member, President Schlissel’s Precision Medicine Task Force

2016-2022 Promotion and Tenure Reviewer, Provost Office

2014-2015 Member, Pharmacology Department Chair Search Committee

2014-2016 Center for Research on Learning and Teaching (CRLT) Advisory Board

2014-2015 Michigan Institute for Clinical Research (MICHR), Education & Mentoring Group Leadership Team Member, Mentoring lead

2013-2021 Michigan Institute for Clinical Research (MICHR), Education & Mentoring Group Leadership Team Member

2009-2013 Member Scientific Review/Research Committee, Michigan Institute for Clinical Research (MICHR) – funded through the CTSA program (NCRR UL1RR024986)

2008-present University of Michigan Depression Center Steering Committee Member

University of Iowa

2005–2007 Office for the Vice President of Research, Scientific Misconduct Committee

1998-2000 Coalition for Long Term Mental Health Care, University of Iowa, College of Nursing

State and County Committees (Michigan)

2006-2012 Washtenaw Community Health Organization Outcomes and Evaluation Committee, Washtenaw County Michigan

State and County Committees (Iowa)

2004–2006 Health Iowans 2020-Mental Health Chapter Team Member, Department of Public Health, State of Iowa

2002-2003 Nominations Committee, Johnson County Pharmacist’s Association (JCPA), Johnson County, Iowa

2002–2003 Programming Committee, Johnson County Pharmacist’s Association (JCPA), Johnson County, Iowa

2001-2002 Past President, Johnson County Pharmacist’s Association (JCPA), Johnson County, Iowa

2000-2001 President, Johnson County Pharmacist’s Association (JCPA), Johnson County, Iowa

1999-2000 President Elect, Johnson County Pharmacist’s Association (JCPA), Johnson County, Iowa

1998–2006 Iowa Pharmacy Recovery Network (IPRN), Iowa Pharmacy Association

1998-2003 Health Iowans 2010-Mental Health Chapter Team Member, Department of Public Health, State of Iowa

1998-2000 Communications Committee, Iowa Pharmacy Association

National Committees and Appointments

2024-2026 Chair, Workforce Development Taskforce, National Center for the Advancement of Translational Science (NCATS)

2022-present Association for Clinical and Translational Science Program Planning Committee

2021-present Workforce Development Taskforce, National Center for the Advancement of Translational Science (NCATS)

2019-2022 Education and Training Committee, American College of Neuropsychopharmacology (ACNP)

2018-2023 Pharmacotherapy Publications Board of Trustees, American College of Clinical Pharmacy (ACCP)

2017-2022 Association for Clinical and Translational Science Career Development Committee

2017-2019 Chair, Precision Medicine Taskforce, American College of Clinical Pharmacy (ACCP)

2016-2021 Association for Clinical and Translational Science (ACTS) Board of Directors

2014 Chair, Member Relations Committee, American College of Clinical Pharmacy (ACCP) Research Institute

2012-2013 President, American College of Clinical Pharmacy (ACCP) Research Institute Board of Trustees

2010-2022 Savvy Psychopharmacology Department Editor, *Current Psychiatry*

2010-2011 Annual Meeting and Spring Forum, Poster Chair, American College of Clinical Pharmacy (ACCP)

2010-2014 American College of Clinical Pharmacy (ACCP) Research Institute Board of Trustees

2009-2010 Pharm.D. Post Graduate Education Summit Planning Committee

2008-2011 Annual Meeting Poster and Awards Chair/Co-Chair, College of Psychiatric and Neurologic Pharmacists (CPNP)

2008-2010 Secretary, Board of Directors, College of Psychiatric and Neurologic Pharmacists (CPNP)

2007-2020 Member, National Alliance for Mentally Ill (NAMI) Scientific Research Council

2006 Pharm.D. Pathways to Biomedical Research, NIH conference Attendee

2006-2007 American Association of College of Pharmacy (AACP) Clinical Scientist Task Force

2007-2009 American College of Clinical Pharmacy (ACCP) Research Institute Mentored Investigator Development Program Committee

2007-2008 American College of Clinical Pharmacy (ACCP) Research Institute Researcher Development Committee

2006-2009 American College of Clinical Pharmacy (ACCP) Research Institute Research Training Committee

2006-2009 Chair, Research Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)

2004-2006 Chair, American College of Clinical Pharmacy CNS Practice and Research Network group

2004–2010 Research Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)

2002–2005 Fellowship Review Committee, American College of Clinical Pharmacy

2001-2004 Chair, Awards and Nominations Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)

2000-2001 Co-Chair, Awards and Nominations Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)

1999–2002 Psychiatry Board Certification Preparatory Course Development Committee, American College of Clinical Pharmacy

1998-2004 Awards and Nominations Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)

1997-1998 Chair, Research/Clinical Practice/Networking Committee ACCP, CNS Practice and Research Network group

Patient-Centered Outcomes Research Institute (PCORI)

August 2012 Patient-Centered Outcomes Research Institute (PCORI) Grant reviewer

National Institutes of Health Reviews

2023-present NCATS Program Grant Reviewer, Clinical and Translational Science Awards Special Emphasis Panel ZTR1 CI-9

2020 Substance Abuse and Mental Health Services Administration (SAMHSA) Grant Reviewer

2016 NIH Precision Medicine Special Emphasis Panel ZRG1 IMST-R (50) R

2015 NIH Precision Medicine Special Emphasis Panel ZRG1 IMST-R (50) R

2012 Patient Center Outcomes Research Institute (PCORI) Reviewer

September 2012 NCATS Therapeutics Discovery Reviewer

July 2012 NIMH Program Grant Reviewer, ZRG1 PSE-B (03) M

July 2012 NIDDK Program Grant Reviewer, Special Emphasis Panel ZRG1 EMNR-Q (50) R-PAR-08-160: Metabolic Effects of Psychotropic Medications

January 2012 NIGMS Program Grant Reviewer, 2012 NIH Director's Pioneer Award Program

December 2011 EMNR Program Grant Reviewer, OD-11-003:  Specialized Centers of Research (SCOR) on Sex Differences (P50).

January 2011 NIGMS Program Grant Reviewer. 2012 NIH Director's Pioneer Award Program

July 2010 NIDDK Program Grant Reviewer, Special Emphasis Panel ZRG1 EMNR-Q (50) R-PAR-08-160: Metabolic Effects of Psychotropic Medications

January 2010 NIGMS Program Grant Reviewer, Special Emphasis Panel ZGM1 PPBC-5 (KB)

December 2009 NIGMS Program Grant Reviewer, Special Emphasis Panel ZRG1 GGGM (52)R

July 2009 NIA Program Grant Reviewer, Special Emphasis Panel ZAG1 ZIJ-3 04

June 2007 NIA Program Grant Reviewer, Special Emphasis Panel ZAG1 ZIJ-8 03

October 2006 NIMH Program Grant Reviewer, Special Emphasis Panel ZMH1-ERB-L-02

July 2006 NIA Program Grant Reviewer, Special Emphasis Panel ZAG1 ZIJ-8 03

October 2005 Committee Chair, NIMH Special Emphasis Panel ZMH1-ERB-L-02

Additional Grant Reviews:

2022-present PhRMA foundation multiple grant mechanisms

2013 Portugal Grant Reviews

2011 ZonMw's 'Klinische Fellows' programme, The Netherlands

2010-present Italian Ministry of Health

2006-2008 American College of Clinical Pharmacy Research Institute

2004 Ontario Mental Health Foundation

2003-2006 University of Iowa General Clinical Research Center

2003-2006 University of Iowa Biosciences Initiative Grant Program

**Other Professional Activities:**

Reviewer:

ASHP Supplemental Standard and Learning Objectives for Residency Training in Psychiatric Pharmacy Practice, 1997

ASHP Supplemental Standard and Learning Objectives for Residency Training in Clinical Pharmacokinetics Practice, 1997

Clinical Positions:

1994-2006 Clinical Pharmacist on Medical Psychiatry Unit (4SE), University of Iowa Hospital and Clinics, Iowa City, IA,

1994-2006 Clinical Pharmacist for Clinical Liaison Psychiatry Team, University of Iowa Hospital and Clinics, Department of Psychiatry, Iowa City, IA

1996-2006 Consultant Pharmacist for IMPACT program, University of Iowa Hospital and Clinics, Department of Psychiatry, Iowa City, IA.

Moderator:

Incorporating Health Services Research into Practice – Parts I and II. College of Psychiatric and Neurologic Pharmacists Annual Meeting, Phoenix, Arizona, May 2011

The Great Eight, American College of Clinical Pharmacy Annual Meeting, Austin, Texas, October 2010.

Central Nervous System Focus Session, American College of Clinical Pharmacy Annual Meeting, St. Louis, Missouri, October 2006.

Psychiatry Platform Presentation Session, American College of Clinical Pharmacy Annual Meeting, Kansas City, Missouri, October 1999.

**Awards and Honors:**

October 2024 Augsburg University, Distinguished Alumni Award

April 2023 Judith Saklad Award, American Association of Psychiatric Pharmacists

April 2023 Kremer's Lecture, University of Wisconsin College of Pharmacy

April 2022 Roland T. Lakey Award, Wayne State University

April 2012 Michigan Institute for Clinical and Health Research (MICHR) Distinguished Mentor Award in Clinical and Translational Research

August 2007 Fellow, American College of Clinical Pharmacy

June 2007 Guest Editor, *Journal of Pharmacy Practice*

August 2006 Editorial Board Member, *Pharmacotherapy*

April 2003 Young Investigator of the Year Award, American College of Clinical Pharmacy

October 2002 Honorable Mention for Best Poster Award, American College of Clinical Pharmacy Annual Meeting

April 2002 Participant in the Future Leaders in Psychiatry Meeting sponsored by the Emory University and Janssen Pharmaceuticals

June 2000 Participant in the New Technology in the Learning Environment (nTITLE) Summer Faculty Workshop sponsored by the Center for Teaching, University of Iowa Libraries, and Information Technology Services at the University of Iowa.

July 1999 Participant in the Summer Research Institute sponsored by the National Institute of Mental Health (NIMH) and American Association of Geriatric Psychiatry (AAGP)

August 1998 Participant in Leadership Pharmacy Conference sponsored by Iowa Pharmacy Association and Pharmacy Society of Wisconsin

November 1997 Best Poster Award, American College of Clinical Pharmacy Annual Meeting

July 1995 American College of Clinical Pharmacy Psychopharmacology Fellowship

June 1992 Hallie Bruce Memorial Award, for outstanding achievement in hospital pharmacy

1991-1992 Kappa Psi Scholarship Honors

1991 Skoglund Memorial Scholarship, Fairview Riverside Medical Center.

1988 Co-founder of the Women's Awareness House at Augsburg College.

1988-1989 Secretary of Orientation Program, Augsburg College.

1987-1989 Orientation Leader, Augsburg College

1988-Present Omicron Delta Kappa National Honor Society, Augsburg College

1987 Holman Memorial Chemistry Scholarship, Augsburg College